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Abstract
Osteoarthritis (OA) is a degenerative disease of the articular joints that affects over 240
million people globally. Despite its overwhelming prevalence, there is no disease modifying
agent currently available to treat the disease, and many treatment options remain palliative in
nature. Potentially effective treatments for OA are limited by probable systemic side effects.
Intra-articular drug delivery systems present a new opportunity for the treatment of OA;
encapsulated therapeutics can be injected directly into the joint, at the area of injury, thereby
bypassing systemic administration and diminishing the chance for side effects. This thesis
describes the research and development of novel polymeric drug delivery systems for intraarticular administration. Initially, a polymer particle delivery platform using poly(ester
amide) (PEA) was developed to encapsulate the non-steroidal anti-inflammatory drug
celecoxib. Drug-loaded particles were successfully prepared, and were characterized
physicochemically and biologically using in vitro and in vivo techniques. Drug was released
in vitro from particles over a period of months, and no cellular toxicity from treatment with
the particles was observed. The particles elicit a favorable host response in vivo when tested
in an ovine model. The PEA particle delivery platform was further developed to encapsulate
and deliver the small molecule, GSK3787, which had been previously implicated as a
potential disease modifying agent for OA. The physicochemical properties of the particles
were characterized including the measurement of the mechanical properties of individual
particles by atomic force microscopy, and it was found that the modulus was in the range of
articular cartilage. The drug-loaded and empty particles exhibited low toxicity to mammalian
cells. In order to establish an even more prolonged release, and greater control over the
system, a hybrid drug delivery system consisting of GSK3787-loaded PEA particles
embedded within a thermally-responsive hydrogel was prepared. This system was evaluated
to understand the effects of particle and drug incorporation on the gel properties including
syneresis, Young’s modulus, degradation, and toxicity. The release of GSK3787 from the
hybrid system was slower in vitro than from hydrogel into which drug was directly loaded
without particles. The hybrid system is promising for further in vivo evaluation. Overall, this
thesis furthered the understanding of polymer drug delivery systems for intra-articular use,
and led to the development of three new systems for potential use in treating OA.
ii

Furthermore, for the first time, a means to deliver the potential disease modifying agent
GSK3787 was developed.
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Summary for Lay Audience
Osteoarthritis (OA) is a degenerative disease of the joints that affected over 5 million
Canadians in 2019, or 1 in 6 people in the country. The prevalence of the disease is
continuing to rise, and it is estimated that 1 in 4 Canadians will be affected by OA in 2035.
Despite its prevalence, non-surgical treatment options remain only modestly effective. Drug
treatments for the disease are greatly limited by their systemic side effects. Non-steroidal
anti-inflammatory drugs for instance, have proven effective at treating the pain associated
with the disease, but have well documented gastrointestinal and cardiovascular side effects.
While no disease modifying agents are currently used for OA treatment, there are a number
of potential agents that cannot be given as traditional oral drugs due to potential negative side
effects. In order to reduce these side effects and to open up the potential of using new disease
modifying agents, drug delivery systems have been proposed. These systems are made from
polymers that are well tolerated in the body, and are designed to encapsulate drug, then to be
injected directly into the joint where they will begin to degrade, and slowly release the drug
to the affected tissue over time. This thesis describes the research and development of three
new drug delivery systems. All of the systems were developed to be injectable, and were
tested for their physical, chemical and biological characteristics, to determine if they were
suitable systems for the delivery of therapeutics in the treatment of OA. The three drug
delivery systems developed in this work have the potential to alter the way that OA is treated,
and increase the feasibility of curing the disease.
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Chapter 1
Introduction
Osteoarthritis (OA) is a leading cause of chronic disability in Canada, with annual costs
projected to reach $7.6 billion by 2031.1 More than 3 million Canadians, and 27 million
Americans currently suffer from this disease, which dramatically reduces mobility,
independence, and quality of life for affected patients.2, 3 OA is also a significant risk
factor for many other diseases such as cardiovascular and metabolic diseases, as well as
depression.4 It is a progressive disease, involving the breakdown of joint cartilage,
synovium, and bone. Currently, no disease modifying agents are available to treat OA,
and care remains mostly palliative. While medications such as anti-inflammatory drugs
can be taken to manage pain and improve joint function, they suffer from significant side
effects and do not alter the disease progression.5 Joint replacement as a treatment for endstage disease also comes with limitations such as risk of infection, potential implant
failure, and altered biomechanics that can cause degenerative changes in other parts of
the body.6
In an effort to elucidate new disease modifying agents (DMA) to treat OA, increasing
research has been performed studying the underlying mechanisms and molecular
processes that take place in OA. Recent studies have identified the peroxisome
proliferator-activated receptor  (PPAR), as a potential target for slowing or halting the
disease.7, 8 The inhibition of PPAR has shown strong potential to provide protective
effects for OA in animal models, as further discussed in section 1.8 of this review.9
Commercial PPAR antagonists are available, however they remain clinically unsuitable
for use. PPAR receptors are present in a multitude of tissues in the body, and play
important roles in fat oxidation and brain function.10, 11 As such, there is a potential for
adverse side effects resulting from systemic administration of PPAR antagonists. As
with many other potential DMAs, PPAR antagonists could benefit from injection
directly into the joint, where drug levels could be high enough to elucidate a response,
without causing systemic side effects. Delivery of medications directly into the joint
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however is subject to rapid clearance by the lymphatic system of the joint. As such, the
need for a drug delivery system becomes apparent for intra-articular (IA) administration
of a number of different drugs. These systems would provide a prolonged release of drug,
in a high dosage, directly to the area of injury, but would not be subject to clearance due
to their larger size. This chapter aims to provide a comprehensive review of drug delivery
systems for IA use, through understanding OA as a disease, its pathophysiology, potential
DMAs, and different examples of IA drug delivery systems.

OA: Definition, Prevalence, Cost and Impact
1.2.1

The disease

OA is a degenerative disorder of the joints that is the most common form of clinically
presented arthritis.1 The disease is multi-faceted, and affects all of the different tissues
that make up joints, including cartilage, synovium, and bone.12 The disease can present in
one or multiple joints. OA can occur in weight-bearing joints, such as the knees or hips,
but can also be found in non-weight-bearing joints, such as those within the hand.13 For
many years the disease was categorized as a mechanical disease, caused by wear and tear
of joints and joint tissues over time. While it is understood that mechanical forces play an
important role in the development and progression of OA, more recently, molecular
mechanisms have been studied in an attempt to better understand the pathophysiology of
the disease. The upregulation of pro-inflammatory cytokines, which can lead to increases
in matrix metalloproteinases, has been shown to lead to the increase in catabolism of joint
tissues, and the decrease of anabolic processes that can repair these tissues.14 The
relationship between mechanical and molecular factors in OA is becoming increasingly
understood, as it is believed that both can play an active role in the disease. An altered
mechanical loading of the joints can lead to abnormal stresses, which can change the
physiology of the joint, whereas an altered physiology, such as inflammation, can cause
an altered mechanical loading, furthering the progression of the disease activity.15 Figure
1.1 shows the relationship between mechanical and molecular factors in OA.
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Figure 0.1: The relationship between abnormal mechanical stress and abnormal
physiological factors in OA. Adapted with permission from reference 12. Copyright
2011, Elsevier.

1.2.2

Prevalence of OA

OA is an extremely common disease and continues to be a major challenge for healthcare
systems as the prevalence continues to rise. In 2019, a study published by Zhao et al.
reported on the prevalence of OA based on patients who sought treatment for the disease,
and it was estimated that the prevalence of OA in the United States was 10.5% of the
population, or 26.5 million people.4 Over the age of 75, it was estimated that the
percentage of people with OA in the US was higher than 25%. In Canada, it was
estimated in 2014 that OA affects 10% of the population over the age of 15, and that over
45% of people over the age of 65 reported the disease in at least one joint.16 Furthermore,
Canadian studies estimated that the average onset age of the disease was in the late 40s,
but that patients went an average of over 7 years before actual diagnosis of the disease by
a physician.16 The rising prevalence of OA shows no signs of slowing, with the Center
for Disease Control (CDC) projecting that by 2030, 67 million adults, corresponding to
25% of the population over 18 will have OA.17 This is compared with the 52.5 million
adults in 2010-2012.
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While the overall numbers of patients with clinically diagnosed OA can be
overwhelming, one of the more prevalent recent statistics is the emerging population
developing OA at a younger age. The rise in prevalence has been a long-standing issue,
with studies suggesting in 2017 that OA prevalence had doubled since the mid 20th
century, attributing it to a number of different factors.18 This increase in younger
populations being affected by OA has also resulted in sharp increases in younger
populations receiving joint replacement surgeries, burdening the healthcare systems with
extremely high costs.5,19,20

1.2.3

Risk Factors

OA has been associated with a number of different risk factors. These include, but are not
limited to, age, genetic susceptibility, obesity, gender, trauma, muscle weakness,
repetitive motions and meniscal or ligament damage.19 It is well known that age is the
largest risk factor that contributes to OA. It has been hypothesized that the increased
prevalence of OA with age is tied to normal biological factors and changes in tissues that
also increase naturally with age.2 The thinning of cartilage, loss of muscle mass, and
oxidative damage all occur more frequently in older populations, and can make joints
more susceptible to damage from other risk factors, such as mechanical damage.
Obesity is another risk factor that has an overwhelming prevalence in OA. It is believed
that obesity plays both mechanical and metabolic roles that lead to the onset and
progression of the disease.20, 21 Increased loading of the joint due to extra weight is a
likely mechanism by which OA occurs due to obesity. Simply overloading of the joint
however is not believed to be the sole cause of obesity induced OA, with failure of
ligamentous and other structural support believed to cause further joint damage and play
a key role in disease development. A recent meta-analysis of studies that looked at weight
loss in OA showed a 5% weight reduction was sufficient to improve symptoms of the
disease.22
Genetic factors have also been shown to play a role in the development of OA. Studies
performed on twins, and closely related family members have shown that there is an
inheritable component of OA, and that there is a larger genetic influence for joints that
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are less affected by mechanical forces, such as hand OA.23 Furthermore, genome-wide
association studies have recently identified specific loci on chromosomes that have been
tied to an increased prevalence of hand and knee OA.24
A number of other risk factors exist for OA, such as joint injuries, bone diseases,
metabolic disorders, repeated stresses, and infections. Injuries to joints have been
increasingly studied and accepted as a means to induce OA. A number of studies have
recently tied injuries that occur from sports, or work-related injuries to the development
of OA. One specific subset of the disease, posttraumatic OA (PTOA), develops after
injuries to the joint. PTOA has been found to account for roughly 10% of all new cases of
OA, and can occur after any number of injuries to the tissues of the joint.25

Costs of OA
The direct healthcare costs associated with OA to various healthcare systems in the world
can vary greatly due to the population, as well as the way healthcare is managed in the
respective countries. Direct costs for OA can include, but are not limited to,
pharmaceuticals, hospitalization, diagnostics, physician visits, rehabilitation, transport
and physiotherapy.5,8,21 In the United States, it was estimated in 2019 that the overall cost
of OA on the healthcare system was over $190 billion US.4 The out of pocket costs for
healthcare in OA patients was reported to be roughly $1400 per year in the United States,
more than double what non-OA sufferers pay. The use of informal care, such as trips to
the pharmacy, over-the-counter (OTC) medications or other treatments can be high for
OA patients, though it is not as often reported, and is hard to fully tabulate.25
Countries with smaller populations, such as Canada, do not have overall charges at the
same magnitude of the US, but still carry a significant burden from the direct costs of
OA. It was estimated that in 2010, the direct cost of OA to the Canadian healthcare
system was $2.1 billion, but that it was expected to rise to $7.9 billion by 2030.8 OA is
also associated with a high number of indirect costs as well. These can be things such as
absenteeism from a workplace for an OA patient, or the lack of productivity due to the
illness.22,23 Premature retirement and even the increased risk of mortality accounts for
another loss of potential income for OA patients.24
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Joint physiology and OA pathophysiology
OA is a disease of the entire joint, with each of the different tissue types that make up the
joint affected by the disease in different ways. Synovial joints make up the majority of
human joints and allow for free movement. These are the joints that are affected by OA,
and are mainly comprised of subchondral bone, synovium, cartilage, and have a viscous
synovial fluid that fills the joint space.

1.4.1

Articular cartilage physiology

The two bones that make up a joint are covered with articular cartilage. When healthy,
articular cartilage has a smooth surface that exhibits a low coefficient of friction—
allowing the bones that make up joint to move freely and smoothly.13 It is viscoelastic
and is designed to distribute loads across the joint evenly. A 2009 review by Fox et al.
described the components and cellular make-up of articular cartilage.26 The cells within
cartilage, chondrocytes, produce extra cellular matrix (ECM), which has two major
components in cartilage: collagen type 2 and proteoglycans. Proteoglycans consist of a
core protein and multiple glycosaminoglycan (GAG) chains. GAGs are polysaccharides
that have negative charges and are used to form proteoglycans which are highly
negatively charged molecules. The negative charge of the GAGs allows for the
movement of charged molecules into the joint, and creates an environment in which
water can fill, thereby swelling the cartilage tissue.27 The swelling with water is what
allows the cartilage to be load bearing, and to dissipate the forces that occur from the
compression of the joint by the subchondral bone. The two GAGs found in the joint are
chondroitin sulfate (CS) and hyaluronic acid (HA).
Articular cartilage is typically 2-4 mm thick, and is comprised of distinct layers, each
with different properties (Figure 1.2). In each of these zones, cells have different
morphologies, activities, and arrangements, and there are differing chemical and physical
compositions. The first zone in cartilage typically consists of flattened cartilage cells, or
chondrocytes, that make up a dense superficial layer. This layer comes into contact with
the synovial fluid, and shear forces of the joint. This first layer is also described as having
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collagen fibers that are tightly packed, and horizontally aligned. Immediately below the
superficial zone of cartilage is the middle zone. This area makes up the bulk of the
cartilage volume and it contains proteoglycans and thicker collagen fibrils. In this layer,
the collagen is not organized horizontally, and packs less closely than in the superficial
zone. Chondrocytes in this zone are at a lower density and are spherical. This zone is
required for absorbing the immediate mechanical forces on the cartilage tissue. The deep
zone of the cartilage has collagen fibers and chondrocytes that are arranged perpendicular
to the surface of the cartilage, and absorb the bulk of the load that is exerted on cartilage
tissue. Finally, the calcified zone is a dense bottom layer that has the highest
proteoglycan and collagen content of the tissue, in addition to chondrocytes which are
densely packed in vertical formation.

Figure 0.2: The structure of articular cartilage. Reproduced with permission.
Copyright Mary Ann Liebert, 2018.

1.4.2

Pathophysiology of articular cartilage in OA

The cartilage is often thought of as one of the most altered tissues in OA. Radiographic
imaging can show the degradation of cartilage, as well as overall thinning of the tissue.28
It is well documented that an increase in catabolic factors and decrease in anabolic factors
leads to damage of cartilage in OA.14 The change in the balance of anabolism to
catabolism has been increasingly studied, however, the overall reasons and causes behind
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this change remain unclear. Once the breakdown of cartilage has begun, it is extremely
difficult to repair. Cartilage is not known for its self-healing capacity, because
chondrocytes typically have a very low proliferation rate.29 Furthermore, the cartilage
tissue is avascular, meaning it is difficult for new growth factors or repair molecules to
make their way to the tissue. The leaking of proteoglycans from the damaged cartilage
have been shown to cause synovial inflammation, thereby leading to further progression
of the disease.
Mechanical degradation of cartilage plays a large role in the pathophysiology of OA as
well. While normal physiologic loading in joints is protective, and actively required to
maintain proper cartilage thickness, the unphysiological loading can cause damage to
joints. In 2018 Cooke et al. showed that the dynamic loading of human cartilage tissue
led to an increase in the surface roughness and cartilage degradation.30 While the change
was noted in healthy cartilage tissue, it was largely altered in tissue that had been
previously diagnosed with OA. Histological preparations showed visible damage in
cartilage after dynamic loading as well, and the damage was once again much worse in
OA patients. The work suggested that mechanical damage can cause cartilage
degradation, and once there is already degradation, the tissues are far more susceptible to
further damage.

1.4.3

Subchondral bone physiology

Subchondral bone refers to the bone that forms an interface between the calcified
cartilage and the trabecular bone (Figure 1.3).31 To date, the exact definition has been
slightly ambiguous with different researchers having different interpretations of the
components of the bone, as well as its depth. The bone is typically described as having a
plate where there is an immediate separation from cartilage, followed by subchondral
trabecular bone underneath.31 The subchondral bone plays an important role in the
function of a healthy joint, and acts primarily as a shock absorber for forces that are
placed upon the joints during normal movement.32 Subchondral bone is much more stiff
than articular cartilage, and as such it works to absorb a large amount of the mechanical
forces in the joint. Subchondral bone has also been implicated for its role in nutrient
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supply, metabolism and remodeling, supplying the tissues of the joint with nutrients that
are necessary to maintain homeostasis.31 All of these factors affect the normal activity of
the articular cartilage, thereby allowing it to continue to function normally.31

Figure 0.3: Illustration of articular cartilage and subchondral bone. Reproduced with
permission from Karsdal et al. Copyright Elsevier, 2008.

1.4.4

Pathophysiology of subchondral bone in OA

Due to the close connection between the subchondral bone and the articular cartilage, the
subchondral bone plays an intricate role in the metabolism of articular cartilage, and
damage to the bone can cause major metabolic changes in cartilage.33 It has been noted
that in early progression of OA, the interface between the subchondral bone and articular
cartilage undergoes distinct remodeling, especially in areas that cartilage damage is
present.34 This remodeling results in increased bone proliferation, thereby increasing the
thickness of the subchondral bone. The mechanism by which bone turnover and structural
degradation of the bone is increased in early stage OA is not fully understood, but a
number of different possibilities have been studied. Repair of microdamage to the surface
of the bone, an increased vascularity of the bone, and a widening porosity, which can
increase the crosstalk between bone and cartilage, have all been studied, and are believed
to play a role.34 As OA progresses, a decrease in mineralization and reduced bone
stiffness are noted, which are believed to be a result of the accelerated bone turnover.
To date, a number of different therapeutic options to treat the subchondral bone and its
role in OA have been studied. Hormonal therapy to block the bone remodeling process,

10

bisphosphonate and calcitonin use, or bone formation agents have all been studied as
potential options for treatment.35 Many of these therapies appear to have promising
results in animal models, but have either failed to provide reproducible results in humans,
or remain inconclusive.

1.4.5

Physiology of synovial membrane

The synovial membrane is a soft tissue that lines synovial joints and tendons, and forms
the fat pad and bursae. The synovial membrane is made up of two distinct layers: the
intima, which is a layer made up of macrophages and fibroblast cells, and the subintima
which is made up of blood and lymphatic vessels, resident ﬁbroblasts as well as
inﬁltrating cells, embedded into a collagenous extracellular matrix. The intimal layer of
the synovial membrane is typically 20-40 m thick in cross-section, while the subintima
can be up to 5 mm in thickness.36 The synovial membrane serves as a barrier to the joint
space, but is not entirely closed off from the rest of the joint. Cells form an imperfect
layer to make up the membrane, meaning there can be transport into and out of the
membrane. A histological preparation of the synovial membrane is seen in Figure 1.4.

Figure 0.4: Histological preparation of the synovial membrane. Image shows synovial
cells (SC), blood vessels (BV) and connective tissue (CT). Reproduced with permission.
Copyright 2011, Bentham Open.
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The synovial membrane provides a barrier that still allows for the movement of materials
to the adjacent tissues of the joint. To retain synovial fluid, the intimal layer of the
synovial membrane exhibits a free exchange of proteins and molecules, while inhibiting
the transit of the hyaluronan that is an important component of the joint fluid. Through
this free movement, the cell types that make up the intimal and subintimal layers work
together to control the volume of the synovial fluid within the joint. The synovial
membrane also plays an integral role in the lubrication of cartilage through the secretion
of lubricin. The synovial membrane also secretes molecules that are imperative for the
nutrition of the joint cells and tissues, through utilization of the blood vessels that lie
within it.

1.4.6

Pathophysiology of synovial membrane in OA

In OA, the most common change in the synovial membrane involves the inflammation
and enlargement of the tissue, known as synovitis. Synovitis is believed to be the largest
driving factor behind the pain associated with OA. This inflammatory response is
hallmarked by an influx of white blood cells to the tissue, which are responding to proinflammatory cytokines that are secreted by cells while the disease occurs. An influx of
macrophages into the tissue is a hallmark of synovial inflammation. It has been
hypothesized that as cartilage begins to break down as a result of OA, the byproducts are
released into the synovial fluid, which are then phagocytosed by synovial cells. This
action amplifies the synovial inflammation. The inflamed synovial membrane further
produces catabolic and pro-inflammatory cytokines, leading to a production of enzymes
which break down the cartilage further. On a macroscopic scale, synovitis as a result of
OA is easily visualized by magnetic resonance imaging (MRI), in which synovial
hypertrophy, and synovial fluid volume can be easily seen in patients that have OA.
Contrast enhanced MRI has been found to be extremely well correlated with radiographic
OA as measured by X-Ray.37

12

1.4.7

Physiology of synovial fluid

The synovial fluid is a viscous solution that is an important component of the joint.
Synovial fluid is typically a clear, beige-coloured, viscous liquid. The typical volume of
synovial fluid in a human knee joint is roughly 1 mL.38 The synovial fluid has a number
of different roles in the normal function of a joint. Its main function is to reduce the
friction between the articular cartilage of the joint during movement, with the main
component that imparts the lubricating qualities being hyaluronan.39 Hyaluronan plays an
important role in cartilage protection and the nutrient transport to cartilage. In addition,
the fluid acts as a biochemical reservoir for a number of different proteoglycans40 and
surface active phospholipids41 that also play a key role in giving the synovial fluid
lubricating qualities. Furthermore, the synovial fluid contains molecules that mediate
communication between cell populations in the joint.38

1.4.8

Pathophysiology of synovial fluid in OA

There is a marked increase in catabolic and pro-inflammatory cytokines that are present
in the synovial fluid of a joint affected by OA. It has been hypothesized that this increase
in cytokines can lead to further degradation of cartilage. In addition, the level of proteins
and overall volume of synovial fluid increase in OA, which can lead to further
inflammation of the joint.38

Disease onset, diagnosis and progression
Patients that are suffering from OA typically present with common symptoms. Joint pain
that is chronic is the most common complaint, but loss of function or natural range of
motion, as well as joint effusions are also commonly described by patients.19 After the
completion of a physical exam, radiographic screening of patients with X-ray remains the
gold standard in OA diagnosis, however MRI can be utilized for a more wholistic view of
the entire joint and all the tissues involved in OA.42 Despite the success X-ray technology
has had in OA diagnosis, it remains imperfect. In many cases patients can present with
radiographic findings of joint space narrowing, but report little to no clinical symptoms.
The opposite can also hold true, with some patients reporting a decrease in the ability to
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use the joint, as well as intense pain, but can show no major changes radiographically.43
Just as the radiographic findings of the disease can differ for patients, the progression of
the disease can widely vary between patients. Progression in some individuals may be
slow, while other patients have reported rapid progression of the disease. Severity can
limit the abilities of patients on a day to day basis, with part of the affected population not
being able to perform normal movements, like standing and walking.17 The disease is
typically monitored by physicians using continued radiographic imaging, alongside
clinical findings and patient reported abilities.28, 42

Current treatments
The treatment of OA remains variable from patient to patient, and despite the prevalence
of the disease, there remains no gold standard for the treatment of OA, nor is there a
disease modifying agent available. The treatment of OA is typically dictated by the
progression and the stage of the disease, as well as individual patient preferences (Figure
1.5). Joint replacement surgery can be used for a subset of patients that have severe OA
that is deemed to have a distinct effect on quality of life. Though the surgery is typically
reserved as a final option, the number of total joint replacements is growing, with more
than 600,000 knee replacements performed in the United States last year.

Figure 0.5: An outline of the current treatments for OA.
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1.6.1

Non-Pharmacologic treatment

Due to the costs associated with OA, and its overall prevalence, it is becoming
increasingly common for physicians treating OA patients to use non-pharmacologic
therapy as a first line treatment method.44 These therapies are typically intended to
control the symptoms before pharmaceutical intervention is required, thereby limiting the
amount of medications required by patients. Many different types of non-pharmacologic
therapies have been suggested for OA treatment, including exercise,45-48 physical
therapy,49 the use of mobility assistance devices such as braces or splints,50
acupuncture,51 nutraceuticals,52-54 weight loss,21, 55-57 and ultrasound.58
Of the current non pharmacologic treatments that are used for OA therapy, exercise and
weight loss are the most commonly utilized therapies. By reducing the overall weight of
patients, the overall load on the joint, and thereby on the damaged tissues, can be
reduced. Weight reduction has shown favorable patient reported outcomes of the disease,
as well as to increase patient reported quality of life.56 Recent studies have looked at the
effect of diet-based weight loss in OA patients,17, 53 as well as exercise-induced weight
loss of OA patients,45 and in both cases have found that the reduction of weight is
beneficial in the management of the disease. Recently, numerous studies have reported
that there is a beneficial effect on the disease from exercise, regardless of weight loss.46,
48, 59, 60

1.6.2

Pharmacologic therapy

Though the non-pharmacologic therapies are gaining momentum in the treatment of OA,
pharmacologic therapies are still commonly used. The history of pharmacologic therapy
for OA is well documented, and the medications that are used in OA treatment have
inherent risks associated with them. The drug rofecoxib, for example, was once believed
to be a gold standard for OA treatment: the potent COX inhibitor was extremely effective
at mitigating pain associated with the disease. However, in 2004 it was voluntarily pulled
from the market because of safety concerns, specifically an increased risk of cardiac
infarctions—a fate that has been common in drugs designed for OA over the years.61
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1.6.3

Systemic pharmacologic treatment

Most pharmacologic therapy associated with OA is taken systemically. Oral medications,
such as acetaminophen, or non-steroidal anti-inflammatory (NSAID)s are typically used,
as they are effective at lowering the pain and inflammation associated with the disease.
These medications are non-specific, and while they are effective, they must be utilized at
high doses to reach beneficial effect in OA treatment. Prescription strength NSAIDs have
been developed as more selective anti-inflammatory agents. Celecoxib and meloxicam,
are two selective COX-2 inhibitors that have been used in OA treatment.62 The potential
side effects of NSAID usage for OA treatment is well documented, and remains an issue.
The link between NSAID therapy and gastrointestinal disorders has been widely studied
and corroborated,63 a problem which is amplified for older patients who are more
susceptible to gastrointestinal side effects, and OA. Furthermore, NSAIDs have
documented cardiovascular side effects,64 making the long term use of NSAIDs
problematic in some patients. More recently, serotonin and norepinephrine reuptake
inhibitor (SNRI)s have been studied as a pharmacologic option for the treatment of OA.
Sold under the brand name Cymbalta, duloxetine has shown promising results in stopping
the pain that is associated with OA, but only treats the symptom, and does not actually
alter the pathophysiology of the disease. Side effects do remain due to treatment with
duloxetine, and it is not currently recommended as a first line therapeutic for OA
treatment.65
Other systemic options for the treatment of OA include topical ointments. Topical
ointments typically have better safety profiles than orally ingested counterparts, and have
the ability to deliver a number of different drugs to the area of injury, such as NSAIDs66.
While topical administration is safer, it has also been noted that the therapeutic benefit of
topically delivered NSAIDs is far less than when delivered orally. Other topical agents
that can be used serve primarily as pain relief agents, such as capsaicin gel, and while
there have been studies showing benefits to using these types of treatment when
compared to placebo, the actual clinical benefits remain unclear.62, 67
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1.6.4

Intra-articular injections

In an attempt to increase the amount of bioavailable drug molecules at the area of injury,
while mitigating the side effects that are seen from systemically administered drugs, IA
injections can be utilized. IA injections have been used in the treatment of OA for over
50 years, and have generally good safety profiles.68 The most common IA injection used
for the treatment of OA is the injection of corticosteroids.69 Methylprednisolone,
triamcinolone and dexamethasone are all commonly used steroids.69 IA injection allows
for a higher dose to be localized at the damaged tissues than could be delivered
systemically.70, 71 Furthermore, the use of an IA injection of allows for the steroids to be
compounded with other molecules to slow their clearance from the joint.72 Adverse
events from corticosteroid injection are documented, but are considered mild or moderate
in most cases.73 However, current steroid injections provide only a short-term benefit and
do not alter the disease course long-term, so there is a hesitance to continue repeated IA
injections.73
Viscosupplementation is a means of replacing naturally occurring molecules within the
joint that are either damaged or lost when OA progresses. These injections are typically
comprised of HA or its derivatives, or chondroitin sulfate.62, 74 It is hypothesized that
these injections improve the viscoelastic properties of the synovial fluid, which helps to
dissipate the mechanical load on joints, and provide better lubrication. There are no major
safety concerns of viscosupplementation, outside of the typical risks associated with the
injection, though the clinical efficacy remains questioned.75

1.6.5

Joint replacement

Depending on the joint affected, the response to the aforementioned therapies, and other
patient specific factors, total joint replacement therapy can be performed. Joint
replacement therapy for OA is typically reserved for extreme cases of the disease, in
which mobility is significantly impaired, or quality of life has diminished severely.76 In
recent years, there has been a growing demand for total joint replacements in both the
knee and the hip, but at the same time there is an anticipated shortage in surgeons that are
willing to perform these operations.76 The risks of joint replacement surgery are well
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documented. Adverse reactions to implants, or infections associated with the surgeries
are known issues, and the failure of the implant begins to occur naturally over the lifetime
of the implant with increased usage, necessitating a new joint replacement, and
subsequent surgeries.77, 78 Recent studies have looked at a minimally invasive procedures
compared to a more traditional approaches, and while there were promising results, there
is still no general consensus on a gold standard for joint replacement surgery.79 Due to the
costs associated with the replacement of joints, and the need for continuous care of
implants, the surgeries typically remain an option that can only be utilized in cases where
the disease has progressed, and is causing major mobility and quality of life issues for
patients.78

Potential disease modifying agents
While the complete pathophysiology of OA is not yet fully understood, there is an
undeniable need to develop disease modifying agents that can alter the progression of the
disease, rather than solely treating its symptoms. Recent research as begun to study the
many different molecular pathways that are involved in the onset and progression of OA,
and through the understanding of these pathways, new potential DMAs have been
proposed. These potential DMAs can have a number of different targets and mechanisms
that work to alter the pathophysiology of the disease, such as pain attenuation or
inflammation inhibition. Recently, newer targets have emerged that could serve to alter
the tissues and their molecular processes, thereby slowing or halting the progression of
OA. Below, potential OA therapeutics are categorized by their classes, and are discussed.

1.7.1

Disease Modifying Agents Targeting Pain

Pain is one of the most commonly associated pathways that is studied for the
development of a potential OA therapeutic. The pain that is associated with OA is often
early onset in the disease, where it is related to initial tissue injury, inflammation, and
increased sensitivity in the tissues around the joint.80 As the disease progresses, increased
pain around the area of injury is associated with the disease, and unlike in other diseases,
the pain that is associated with the initial injury in OA does not subside with time. Due to
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the widespread and variable nature of pain in OA, a number of different mechanisms
have been studied. Despite the overwhelming prevalence of pain in OA, the targeting of
pain as a potential for modification of the disease has been contested in the research
community. However, as the underlying mechanisms of pain in OA become increasingly
understood, a means to halting the processes driving pain can be developed. Recently,
the synergistic relationships between the modification of pain mechanisms and
inflammation, or structural alteration within the joint have been researched, leading to the
belief that pain is indeed a potential drug target that can modify disease.77

1.7.2

Ion Channels

One pathway that has been studied for its effect on pain in OA is the activity of ion
channels; a number of different ion channels have been implicated for their roles in OA.
For example, the TRP Vanilloid 1 (TRPV1) receptor was the target of a new molecule
developed by Centrexion Therapeutics, known as CNTX-4975.81 The TRPV1 receptor
had been initially identified in 2013 as a potential target .82 This molecule is a TRPV1
agonist—a capsaicin derivative that stimulates unmyelinated C-fiber afferents, resulting
in the secretion of Substance P, which provides a desensitization of pain fibers.83 In 2019
CNTX-4975 advanced into phase IIb clinical trials with the US FDA, and has shown a
distinct reduction in pain over 24 weeks of use. Though some of the TRPV1 antagonists
have had their trials ultimately stopped for safety concerns, a number of these molecules
are still currently being researched and appear promising. Negative side effects and safety
concerns have still been noted, and it has been recommended that many of these TRPV1
antagonists utilize a non-systemic mode of administration to mitigate potential side
effects.82, 84, 85 NAV 1.8 is a voltage gated sodium channel that has been implicated in the
mechanotransduction in pain in OA. It was found in a recent study that the application of
a selective NAV 1.8 blocker of the sodium channel was helpful in decreasing the
nociceptive transmission from the tissues of the joint, thereby leading to a reduction in
overall pain.86 The pathway has been tested in local, topical, and oral administration
routes thus far, and has shown promising safety results.86
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1.7.3

Nerve Growth Factor

Nerve growth factor (NGF) is a neuropeptide that is released during injury or
inflammation, and has been implicated as a main cause of pain in OA. NGF has been
shown to bind to Tropomyosin Kinase A (TrkA), which can then lead to an enhanced
perception of pain, as well as a triggering of the initial pain response. It has been
hypothesized that through the inhibition of the NGF signaling pathway, there may be a
decreased sensitization to pain from both inflammatory and non-inflammatory sources.
The inhibition of the NGF signaling pathway has been studied through different
mechanisms. One such example is the use of monoclonal antibodies, which had been
studied and deemed efficacious in preclinical studies. In clinical trials however, safety
concerns became quickly apparent, and these findings brought the initial clinical research
of NGF targeting monoclonal antibodies for OA to a near standstill.87 In recent years
however, new research on the use of human monoclonal antibodies as well as NSAID
combination therapy have emerged, and appear to be promising avenues that could
potentially deliver a new treatment of OA.88, 89 Small molecules have also been
investigated as a means to block NGF pathways, but to date none have emerged as usable
candidates.90

1.7.4

Other pain receptor targeted disease modifying agents

Opioid receptors have been studied for the treatment of OA pain. The use of opioids in
OA treatment remains a widely debated topic, due to the associated side effects with
opioid treatment, including dependence. In an attempt to make opioid use more
applicable to OA patients and mitigate side effects, new research has been performed
with attempts to change the mechanisms of action of the drugs. Alterations in the drugs
have allowed for the development of opioids that act peripherally, rather than centrally,
which are believed to be safer methods of opioid use, while still maintaining the
efficacy.91
Recent work in 2015 by Sophocleous et al. studied the effect of a CB2 agonist to the type
II cannabinoid receptor. Studies appeared initially promising in preclinical animal
models, but the results were not reproducible in human models of OA.92 Despite these
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results, the use of cannabidiol (CBD) remains a widely studied area in OA, with more
recent work in 2017 by Philpott et al. showing that the administration of CBD in rat
models of OA worked to attenuate the progression of OA, through a reduction in joint
inflammation.93 The decrease in inflammation was coupled with lower pain
measurements in the animals. Similar results using CBD were shown in 2016 by
Hammell et al., where CBD was administered topically, and led to significantly reduced
joint swelling as well as the absence of pain in animals treated.94

1.7.5

Disease Modifying Agents targeting Inflammatory Modulation

It is widely understood that inflammation plays a role in the progression of OA; an
increase in inflammatory modulators has can lead to an increase in pain, as well as
degradation of the joint tissues.12 As such, a number of recent studies have focused on
controlling the inflammatory signaling cascades through the control of cytokines.

1.7.6

Cytokines

A number of pro-inflammatory cytokines have been associated with OA. As reviewed in
2011 by Kapoor et al. cytokines such as interleukin (IL)-1β, IL-6, IL-1α, IL-15 have all
been found to be increased in the synovial fluid of joints affected with OA.33
Furthermore, tumor necrosis factor (TNF)-α, has been identified as a major
proinflammatory cytokine that is associated with the progression of OA.33 TNF-α and
IL-1β are believed to play a role in the signaling of NGF, thereby leading to not only
inflammation, but an increased pain response as well.95
Due to their overwhelming presence in OA, IL-1 α and IL-1β are common targets for
inflammatory modulation. IL-1 stimulates neutrophil migration in OA, and activates
articular cells to produce mediators that are involved in joint inflammation and
destruction.96 Furthermore, IL-1 has inhibitory actions on the production of new
extracellular matrix components.97 The two aforementioned cytokines both bind to the
same receptor, (IL-1R1) making receptor antagonism of IL-1R1 a common target for
drug development. Anakinra for instance, is an IL-1R1 receptor antagonist that has
shown clinical promise for treatment in OA patients. A 2017 study showed a beneficial
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effect of using anakinra for treatment in large joints, but it was recommended that only
patients who had failed first line therapy receive the medication.98 These results have
been directly contradicted in the past by other studies though, leaving the clinical
recommendations regarding anakinra in a state of flux. Other attempts have been made
using antibodies, such as lukitizumab, to control the activity of IL-1R1.99 The effects of
lukitizumab have been highly variable in different trials, and it is not currently being used
to treat OA.
Tumor Necrosis Factor (TNF)-α is another common target cytokine for the treatment of
inflammation in OA. Anti-TNF-α therapies have been developed and clinically available
for a number of years in inflammatory conditions such as rheumatoid arthritis,
inflammatory bowel disease, and psoriasis. A 2012 paper reported on the efficacy of antiTNF-α administration in the treatment of OA, and while it concluded that there were
promising results in initial human trials, more work has to be done to complete full trials
with correct controls and appropriate patient levels.100
A number of other cytokines have been identified as potential targets for OA treatment,
such as IL-10, IL-6, and interferon β. All of these are currently within studies in the FDA
to determine the efficacy and safety of treatment, though no results have been posted to
date, and their future as potential candidates for DMAs remain unclear.14

1.7.7

Other Inflammatory Pathways as Potential Disease
Modifying Agent Targets

Certain molecular pathways in the body have been determined to play a role in the
production of inflammatory cytokines, and other mediators of inflammation. For
example, the nuclear factor-κB (NF-κB) is integral to the production of pro-inflammatory
cytokines, and has been implicated recently in OA. The inhibition of (NF-κB) was
targeted by a compound called SAR113945 in 2017. In administration of this inhibitor, it
was noted in phase I trials that there were beneficial effects, however phase II trials have
failed to demonstrate similar responses.101
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P38 mitogen activated protein kinase (MAPK) is another example of a potential target for
a disease modifying agent in OA. P38 MAPK is a pathway that is associated with the
synthesis of pro-inflammatory cytokines, and the inhibition of p38 MAPK has been
targeted as a means to attenuate the progression of these cytokines. Much like molecules
targeting the NF-κB pathway, the treatments associated for p38 MAPK have been mostly
underwhelming, with one report of a clinical reduction of pain for 4 weeks post-injection,
but no clinically approved p38 MAPK molecule to date.102

PPAR Antagonists as a DMA for OA treatment
In 2015, Ratneswaran et al. showed that activation of PPAR resulted in the degradation
of cartilage extracellular matrix in explant culture of rat limbs.9 Furthermore, cartilagespecific PPAR knockout mice were protected in a PTOA model involving
destabilization of the medial meniscus surgery, suggesting that PPAR promotes PTOA.9
It was elucidated from these studies that PPAR antagonists could potentially provide a
protective or even therapeutic effect for OA.
PPAR antagonists are known, and are commercially available. GSK0660 was first
developed in 2009, and was found to have an IC50 of 155 nM against PPAR and nearly
10-fold selectivity over other PPAR subtypes. However, the molecule had poor
bioavailability, so was not further explored by Glaxo Smith Kline (GSK).103 This led to
the development of GSK3787, a second PPAR antagonist that was demonstrated to
antagonize PPAR in vivo with high specificity through covalent binding to Cys 249 in
the PPAR binding site.104
In 2017, Ratneswaran et al. performed a pilot study to demonstrate the potential
for PPAR antagonists to inhibit OA progression. Sprague-Dawley rats underwent
anterior cruciate ligament transection and partial medial meniscectomy (ACLT/PMMX)
surgery followed by treatment with DMSO (vehicle control) or GSK3787 administered
subcutaneously for 30 days at 1 mg/kg/day. Over the 4 weeks post-surgery, rats that
underwent ACLT/PMMX with DMSO treatment got progressively worse, with functional
impairments in mobility including increased rest time, decreased movement time, and
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decreased vertical activity episode counts. These rats also demonstrated decreased
loading of the operated limb, while PPARδ inhibitor-treated rats did not experience
similar declines in functional activity and limb loading. This data suggested that PPARδ
inhibition prevents functional limitations induced by damage in part, indicating its strong
potential as a therapeutic agent in OA.
PPAR receptors are prevalent throughout the body, where they play important roles.10,
105

PPAR agonists have been investigated for the treatment of metabolic diseases, such

as diabetes and obesity, as it has been shown that activating PPAR can increase fatty
acid metabolism, improve insulin sensitivity, and decrease serum glucose.106-109
Furthermore, PPAR is the predominant PPAR subtype in the brain, where it plays a role
in cognitive function.110, 111 In the short-term pilot study of GSK3787, metabolic effects,
as measured by abnormalities in weight gain, liver weight, or blood glucose were not
observed, but a detailed toxicology study was not performed, and daily systemic
administration of this drug is not feasible over the long-term due to the high risk of side
effects. For use in OA, the direct delivery of the drug into the joint would allow for levels
of GSK3787 required for efficient PPAR inhibition in the joint. To date, no study has
examined the effect of IA injections of GSK3787 for the treatment of OA.

Intra-articular drug delivery systems
IA administration of drugs to treat OA remains paradoxical in nature. Injection of drug
molecules directly to the site of injury can potentially allow for high concentrations of
drug to reach the target tissues. The joint however, is extremely efficient at clearing small
molecules from the synovial fluid, meaning the high drug concentrations are not likely to
last for a prolonged time. Free drugs are removed from the IA space by lymphatic
drainage within a few hours, so they often cannot reach their targets at sufficient levels
over the required period of time to achieve a therapeutic effect.112 Many drugs that have
been studied with IA injections have shown half-lives in the synovial fluid of 1-5
hours.113 The short half-life of drug molecules that are injected into the joint can be
explained, at least partially by the make-up of the synovial lining. Synoviocytes have the
ability to synthesize HA. Macrophages within the synovial membrane work to clear the
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joint fluid of debris. Furthermore, the lining of the synovium is discontinuous; there are
gaps 0.1-5 microns in diameter, through which any free drugs that are injected can easily
flow, ultimately reaching the blood circulation.114-116
Given the rapid clearance of free drugs after IA injection, many OA therapeutics would
benefit from encapsulation into delivery systems that provide prolonged release. These
systems would not only afford the opportunity to deliver drugs to the affected tissue at
higher doses than what could be delivered systemically, but would decrease the required
frequency of IA injections, so discomfort for patients as well as potential complications
associated with injection would be minimized.117, 118, 119 A number of delivery systems
have been explored for the IA delivery of OA drugs.120 Examples of IA drug delivery
systems, their potential benefits and limitations, as well as results of studies, are
described below.

1.9.1

Liposomes

Liposomes are a common class of drug delivery system composed of a phospholipid
membrane encapsulating an aqueous core (Figure 1.6). Drugs can be loaded into the
membrane or aqueous core. Liposomes are generally designed to slowly release drugs via
diffusion through or out of the phospholipid membrane. A number of liposome systems
have been developed and used for IA use.

Figure 0.6: The structure of a liposome.
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In a 2013 study by Dong et al., cholesterol and soybean phosphatidylcholine were
combined with the NSAID celecoxib, and liposomes were synthesized using a film
hydration technique.121 Film hydration involves dissolving the lipids and drugs in a
common solvent before evaporating the solvent leaving a film. Upon resuspension in
water, lipids form a natural bilayer, thereby entrapping drugs.122 In the study, liposomes
were found to have high encapsulation efficiencies, of roughly 99%. Though the authors
showed that they could slow the release of celecoxib through the addition of HA to the
liposome, nearly 100% of the loaded cargo was still released after just 48 hours. In vivo
testing in a rabbit model showed that the liposomes provided a more beneficial effect
than the injection of free drug, though measurements were taken only once at two weeks
post-administration.
In other cases, liposomal formulations developed for IA use provided a more prolonged
drug release than 48 hours. In 2015, Pradal et al. studied the loading of a p38 MAPK
inhibitor, VX-745, into a liposomal delivery vehicle.102 In this study, cholesterol was
again used with dipalmitoylphosphatidylglycerol and distearoylphosphatidylcholine to
prepare the liposomes. The system was developed to overcome solubility issues and the
rapid recrystallisation of the drug when in contact with an aqueous physiological
environment. One key finding from the study was the improved drug resident time when
compared to an injection of free drug alone, showing promise for the administration of IA
liposomes.
Edwards et al. continued to work on liposomal formulations for IA use. A liposome was
developed using 1,2-dipalmitoyl-sn-glycero-3-phosphocholine. Iohexol, a CT contrast
agent, was used as a model drug, and it was determined that when encapsulated within a
liposome, the half-life was 124 hours in the joint, compared to 3 hours when injected
without the use of a liposome.123
While liposomes have an ability to encapsulate drugs, and due to their larger size, should
prolong joint residence time, there are a number of drawbacks that make the use of
liposomes for IA use extremely difficult. In particular, liposomes have a high water
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content, and as such their mechanical properties are typically insufficient to survive the
mechanical forces within the joint.

1.9.2

Nanoparticles

Nanoparticles have been widely used as drug delivery platforms for IA use,124 cancer
treatment,125 ophthalmic treatments126 and other areas. For use in drug delivery
applications, nanoparticles are typically synthesized from biodegradable polymers, and
have the ability to encapsulate a variety of drugs. As nanoparticles degrade, the loaded
drug is released from the system or it may diffuse out prior to degradation. Due to the
relative ease of synthesis, and diversity of nanoparticles, a number of different types have
been developed for IA use. Nanoparticles can fall into a few different categories, and are
closely related to larger sized microparticles. A nanoparticle is typically described as
100-500 nm in size, whereas microparticles are larger, above 1 μm in size. The structure
of particles, either nano or micro, is depicted in figure 1.7. Typically, IA nanoparticle
formulations that have been developed can be broken down into two main subcategories:
nanoparticles for the delivery of drugs into the synovial fluid, and nanoparticles that are
designed to diffuse throughout the surrounding tissues.

Figure 0.7: The structure of a solid core polymer nanoparticle.
In 2007, Thakkar et al. developed an IA nanoparticle delivery system that encapsulated
the NSAID celecoxib. Here, glycerol was used to create solid lipid nanoparticles. The
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average diameter was reported to be roughly 250 nm, and a drug loading percentage just
over 4% was achieved. They measured the in vitro drug release from the nanoparticles
and found that after 7 days 95% of the loaded celecoxib had been released.
Natural polymers have also been used to make nanoparticle formulations for IA use. HA
and chitosan were used by Ryan et al. in 2013 to develop a nanoparticle that encapsulated
salmon calcitonin.127 The diameter of the nanoparticles was 163-193 nm, and the release
of the loaded cargo was between 60 and 80% in PBS after 6 hours. The particles were
found through a study in mice to exhibit more benefit in terms of the reduction of
inflammation than drug suspensions or hydrogels. Kang et al. made nanoparticles from
naturally derived chitosan in 2016.128 The particles were 150 nm in diameter, and were
not loaded with a drug cargo, but instead were conjugated with kartogenin, a small
molecule that has been proposed to promote the repair of damaged cartilage.
Nanoparticles remained localized in the joint for up to 24 days post injection, and when
OA was surgically induced in rats, the treatment with the nanoparticles led to a
statistically lower score on the Osteoarthritis Research Society International (OARSI)
scale, which grades histopathology of OA and reflects depth of the lesions and extent of
OA over the joint surface. It was hypothesized that the nanoparticles led to a more
efficient differentiation of chondrocytes, and therefore had a protective effect against OA
degradation.
In another example of solid lipid nanoparticles for IA use, Jain et al. studied a
nanoparticle formulation created from a mixture of Pluronic F68, stearic acid, citric acid
and lecithin in 2014.129 The nanoparticles had a diameter of about 400 nm, and compared
to the work provided by Thakkar, had a higher drug loading at 15.6%. Diacerein, an
anthraquinone that inhibits IL-1B, was encapsulated. A rapid release of the loaded cargo
was noted, with 40% being released after just 4 hours in vitro. Despite the rapid release of
drug, it was noted that when tested in vivo the particles were able to come into close
contact with the articular cartilage, though their diffusion into the cartilage was not noted.
This led researchers to conclude that the system could be promising for the use of
cartilage targeted therapies, such as tissue specific disease modifying agents.
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Synthetic polymers have also been used for the synthesis of nanoparticles for IA delivery.
Morgen et al. in 2013 showed that when using polycaprolactone-block-poly(ethylene
oxide) (PEG), coated with positively charged dextran derivatives as external shells, they
could prepare nanoparticles that were cationic, and were then able to crosslink with the
negative charges on HA.130 These nanoparticles had diameters between 100 and 150 nm,
but had a longer retention time in the joint of six days, which was believed to be a result
of the interactions with HA. Poh et al. formulated nanoparticles from another synthetic
polymer source: PEGylated poly(N-isopropylacrylamide) (pNIPAM).131 The
nanoparticles were prepared with disulfide crosslinks to ensure degradability, and were
designed to deliver anti-inflammatory peptides directly into chondrocytes. These
nanoparticles had diameter of 237 nm, and a higher drug loading of around 35%.
Challenges with the nanoparticle delivery systems for IA use remain. While the systems
are well tolerated, the resident joint time of nanoparticles remains low. Nanoparticles that
are injected are subject to clearance from the joint over 2 days to around 2 weeks. Despite
this shortcoming, nanoparticles continue to hold promise for the delivery of drugs to
cartilage, and for their potential to diffuse through the tissues of the joint, such as
cartilage or the synovium.

1.9.3

Microparticles

Whereas the rapid clearance of nanoparticles from the joint is often attributed to their
small size, microparticles are larger and can potentially be retained longer, making them
useful for IA delivery. Microparticles are commonly defined as being larger than 1
micron in diameter, and can have diameters of up to 100 μm. The microparticle platform
has been used in a wide array of applications, such as painting or imaging. Within their
use in drug delivery, a number of different diseases have been investigated for potential
treatment with microparticle drug delivery systems. For example, a number of
microparticles have been considered for treatment of cancer,132 and more recently their
use for the treatment of type II diabetes has been studied.133 Microparticles for drug
delivery formulations have been commercialized, with a number of FDA approved
systems on the market today; Ozurdex is one example, that utilizes a microparticle
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formulation to deliver dexamethasone through an intravitreal injection into the eye.83 A
number of different studies have been performed to assess the feasibility of
microparticles for IA drug delivery.
Though there are seemingly fewer examples than compared to nanoparticles,
microparticles can also be prepared from natural polymer sources. Chitosan is a natural
polymer that has been widely used in the preparation of microparticles for IA use. In
2012, Chen et al. used chitosan to develop a microparticle system for IA drug delivery.134
The study looked at the encapsulation of brucine, a drug that is not as commonly seen in
studies for OA, but is known for its analgesic and anti-inflammatory properties.135 The
particles were determined to have a diameter of 2.45 μm, and released between 70 and 80
percent of the loaded cargo after 60 hours. They were found to be well tolerated by the
synovium in a rabbit model, but the joint retention time was low.
Chitosan was also used as the polymer in a 2014 study by Kang et al.128 Researchers
followed the same preparation methods as they did when creating nanoparticles, but
aimed for a larger sized particle. The particles were 1.8 μm in diameter, and although
they were well tolerated, the microparticles exhibited a faster release than the
nanoparticles, and no significant difference was noted in joint retention between microsized and nano-sized particles over 24 days.
Inorganic polyphosphate was used to make microparticles for the delivery of zoledronic
acid, a bisphosphonate, in a study by Müller et al. from 2018.136 Zoledronic acid is
commonly used to treat bone disorders, and it was determined that it may have a
protective effect on articular cartilage as well, making it a promising agent for OA
treatment.137 Interestingly, the particles were smaller than what is typically described as
microparticles, having a diameter of only 60 nm, and were described as having a mesocrystal structure that formed overall structures of up to 500 nm in size.
A number of different synthetic polymers have been used to develop microparticles for
IA delivery. Synthetic polymers can be useful because they can be highly tuned, thereby
changing their properties and their potential for use in drug delivery systems. The most
extensively used synthetic polymer in the preparation of microparticles for IA treatment
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is poly(lactic-co-glycolic acid) (PLGA). PLGA is commonly used due to the fact that it is
well tolerated in vivo, biodegradable, has variable erosion times, tunable mechanical
properties and is approved for use in multiple medical and dental applications by the
United States Food and Drug Administration (FDA).138
PLGA microparticles are already approved by the FDA for IA delivery to treat OA. In
particular, Flexion Therapeutics’ FX006 is marketed under the brand name Zilretta.
These particles are about 45 μm in diameter, are loaded with the corticosteroid
triamcinolone acetonide, and exhibit a prolonged release of the loaded therapeutic when
tested in a rat model.139 The particles were well tolerated in preclinical studies, and in a
recent Phase II trial it was determined that the particles were able to provide persistent
pain relief for up to 12 weeks when compared to a placebo injection.
Other researchers have also used PLGA microparticles to encapsulate a variety of drugs,
and investigated their efficacy for IA administration. In 2013 for instance, Ko et al.
encapsulated sulphoraphane, a natural organosulfur compound, in particles that were 15
μm in diameter. The system exhibited a prolonged release; only 6% of the loaded cargo
was released after 30 days in vitro. In rats that had OA induced by a surgical method, the
microparticles delayed the progression of OA. Gomez-Gaete et al. prepared PLGA
microparticles in 2017, encapsulating Rhein, an anti-inflammatory.140 The size of the
prepared microparticles differed in this study, with the particles measured to be about 4
μm in diameter. Interestingly, the release properties of these particles were vastly
different than the aforementioned system. A rapid release of the loaded molecule Rhein
was observed, with 45% of the loaded cargo released over 24 hours in vitro. The particles
were once again well tolerated, and remained localized in the joint even 1 month after
injection, but were without drug at this time. In 2018, Maudens et al. incorporated
dexamethasone in PLGA microparticles.141 The particles were 10-15 μm in diameter and
were able to incorporate nanocrystalline domains of the drug within the particles in order
to prolong the release of the drug over 3 months.
Another aspect of PLGA that makes it attractive for use in microparticles is the ability to
blend the polymer with other polymers to alter the properties of the drug delivery system.
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Indeed, multiple examples of blending PLGA with other polymers to prepare
microparticles for IA use exist. One example was a study by Goto et al. in 2017 in which
PLGA was blended with gelatin to develop microparticles.142 Fluvastatin was
encapsulated within the microparticles which were about 25 μm in diameter, and the
particles released only 27.5% of the loaded cargo after 7 days in vitro. It was determined
in vivo using a rabbit model that the delivery of a statin could have potential beneficial
effects on OA, as it was found to inhibit the degradation of cartilage after surgical
induction of OA.
One specific class of synthetic polymers that has garnered increasing interest in recent
research is poly(ester amide)s (PEAs). Characterized by the presence of both ester and
amide bonds, and often containing amino acids, PEAs have highly tunable structures and
properties. PEAs containing various amino acids, as well as different spacers between the
ester and amide bonds, have been extensively studied. Furthermore, PEAs have shown
excellent compatibility with cells when used as scaffolds for tissue engineering.143, 144
The tunability of PEAs make them especially promising for IA drug delivery systems. In
2016, Janssen et al. studied the development of microparticles from PEAs that were
responsive to stimuli.145 The particles were made from a PEA that was comprised of three
random blocks, and had the NSAID celecoxib loaded within them. The particles had a
wide range in diameters from 10-100 μm. In vitro drug release was promising, with an
initial burst noticed, but at 80 days in release medium only 50% of the loaded cargo had
been released. In vivo it was seen in a rat model that the particles did degrade over 12
weeks, but no side effects were noted from the degradation of the particles. Furthermore,
it was shown that the polymer particles were able to respond to external stimuli—serine
proteases in this case, to increase the rate of release of loaded cargo.
Microparticles are very promising for IA drug delivery, as evidenced by their FDA
approval and clinical use. Despite this, challenges still persist with their use. Concerns
with microparticles include the potential for the particle degradation products (depending
on their compositions) to induce adverse inflammatory reactions in the joint.146, 147 In
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addition, there is a potential for the particles themselves to cause irritation in the joint if
their mechanical properties are not compatible with joint tissues.148

1.9.4

Hydrogels

Hydrogels are another highly tunable class of drug delivery systems that are promising
for IA delivery. The polymers used to make hydrogels can be derived from natural
sources, such as HA or collagen, or synthetically prepared polymers, such as PEG.149 Not
only can different polymer structures be used to develop hydrogels, but the crosslinking
mechanisms can be varied as well. Physical crosslinks can be induced through changes in
temperature, pressure, light, pH, salt concentration, or electric field. The junctions that
form in a physically crosslinked system are more transient and can range from chain
entanglement to ionic or hydrophobic interactions. Chemically crosslinked hydrogels are
another class of hydrogels that have more permanent junctions. Linkages here can come
from the addition of different molecules to induce chemical changes, such as covalent
bonds. Hydrogels designed for IA use have employed physical crosslinks, covalent
crosslinks, or a combination of both. Examples of hydrogels prepared for IA use have
followed a wide range of preparation methods as well. A representation of both
chemically and physically crosslinked hydrogel networks is depicted in Figure 1.8.

Figure 0.8: Hydrogel networks with varying gelation mechanisms. (A) Shows
physical crosslinking with two proposed mechanisms: bridging of hydrophilic chains (top
left), and micelle agglomeration (bottom left). (B) Shows a covalently crosslinked
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network before and after gelation is induced. Polymer chains seen in blue have covalently
crosslinkable groups on their backbone (green).
Many of the early examples of hydrogels designed for IA use involved naturally derived
polymers. In 2002, Barbucci et al. described a hydrogel prepared from HA that was
designed to release HA to the joint for chondrocyte protection. In a rabbit model, the
researchers elucidated that the hydrogel had a longer resident joint time than injections of
HA alone, which resulted in improved chondrocyte density and appearance.150
Furthermore, hydrogels made from gelatin were studied by Saito et al. in 2009. Other
hydrogels that were prepared from natural sources include those prepared from
alginate151 and chitosan,152 two materials that were deemed to be similar to HA, and
could act as a viscosupplementation method. While most natural polymers used for IA
hydrogels were for viscosupplementation, more recently, synthetic hydrogels have been
derived to deliver encapsulated therapeutics. PEG is an important synthetic polymer that
has favorable properties in vitro and in vivo, leading to its use in many different hydrogel
systems.
Physically crosslinked hydrogels can be prepared by a variety of methods, such as
varying the temperature, or combining polyelectrolytes with multivalent ions of opposite
charge.153 Thermally induced crosslinking mechanisms are especially common for
hydrogels that are designed for IA use, due to the ease of injection of a free-flowing
liquid, followed by a rapid transition to a hydrogel upon reaching physiological
temperature.
Early examples of thermo-responsive, physically crosslinked hydrogels were studied in
2012 by Petit et al. In their work, two different thermo-responsive poly(ε-caprolactoneco-lactide) (PCLA)-block-PEG-block-PCLA triblock copolymers (Figure 1.9) were
prepared - one that was capped with a hydroxyl end group, and one that was capped with
a hexanoyl end group. They were then mixed at differing ratios to form hydrogels.154 The
researchers determined the crosslinking to occur from an entropically driven increase in
the polymer-polymer interactions at higher temperature, resulting from dehydration of the
PEG and polyester copolymers, and leading to aggregation. The gelation process was
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reversible upon a return to lower temperatures. The study found that the rheological
properties, as well as degradation, were easy to modulate, and led to another study
involving the IA administration of a hydrogel made from the PCLA-PEG-PCLA
copolymer, but with an acetyl end cap.155 The rheological properties of this gel were
studied and it was found that the storage modulus (G’) was ~200 Pa. In 2014 Petit et al.
studied these PCLA-PEG-PCLA hydrogels, loaded with celecoxib, both in vitro and in
vivo. In vitro drug release studies of celecoxib showed that about 40% of the loaded cargo
was released after 75 days.156 In vivo, celecoxib was measurable in the synovial fluid
after 30 days, although levels were below 1 μg/mL after 5 days.157

Figure 0.9: PCLA-PEG-PCLA structure.
In 2018 Prince et al. worked on a similar hydrogel, made from PCLA-PEG-PCLA
copolymers with acetyl end caps but using different PEG lengths ranging from 15003000 g/mol, and attempted to load different drugs into the hydrogel networks. The effects
of drug loading on the compressive moduli and rheological properties were studied.158 As
with other thermo-responsive gels, gelation occurred rapidly at 37 C , and was
reversible. However, the incorporation of drugs into these hydrogels had significant
effects on their physical properties. For instance, the addition of methotrexate to the gels
increased the viscous modulus, G”, of the gel by nearly 500 Pa, while the loading of
celecoxib raised it by only roughly 200 Pa. The incorporation of drug decreased the G’ of
the gels for all drugs tested, showing that it is important to examine the effects of drug
loading on gelation.
The incorporation of kartogenin into a thermo-responsive hydrogel was studied in 2019
by Wang et al.159 In their study, a hydrogel was prepared from a PLGA–PEG–PLGA
triblock copolymer, and kartogenin was incorporated after the gel had formed. The small
molecule did appear to release from the gel at a rapid rate, with a distinct burst release
noted between 0 and 2 days; almost 25% of the loaded cargo was released in this time.
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The release of kartogenin was measurable for up to 20 days, at which point 80% of the
loaded cargo had been released. To determine the efficacy of the gel, researchers
performed gene analysis post-injection in a rabbit. Kartogenin thermogels exhibited an
enhanced expression of hyaline-cartilage specific genes COL-2 and AGC, and inhibited
the expression of matrix metalloproteinase (MMP-13), indicating a positive effect on OA
progression.
Non-covalent hydrogels have also been developed from natural polymers. The mixture of
high molecular weight HA and Pluronic F127 (Figure 1.10) was studied in 2017 by Jung
et al.160 It was hypothesized in this work that the inclusion of the HA would lead to a
stronger hydrogel that was capable of a prolonged joint time and release of loaded
NSAIDs. The gelation of the hydrogel was measured through cloud point measurements,
and the authors observed that at about 37 C, the system gelled. It was noted that this was
only seen in the mixture of Pluronic 127 and HA, but not with either polymer alone. The
viscosity of the material was measured over different temperatures, and it was seen that
the gel had a viscous modulus of around 700 MPa at 37 C. In vitro drug release was
studied using piroxicam (PX) as a loaded drug. The system did show a prolonged release,
but it was less prolonged than other hydrogel systems had reported. About 50% of the
loaded cargo had been released after 250 hours, which was longer than other pluronic
based hydrogels that had been tested, but lower than the amount of time that would be
desired for an IA injection. The in vivo pharmacokinetics showed that the PX loaded
hydrogel had a significantly longer half-life, and a higher bioavailability than current
clinically available PX injections, though no comparison to other hydrogels was
performed.
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Figure 0.10: The mixture of Pluronic F127 and Hyaluronic acid to form a hydrogel.
Reproduced with permission from reference 157. Copyright 2017, Elsevier.
Li et al. examined a different hydrogel synthesized from Pluronic F127 (PF) in 2018.161
In addition to PF, this gel was made with GAGs, and bone morphogenetic proteins, and
was designed to mimic the extracellular matrix of cartilage cells. Rheological
characterization of the gels showed a distinct transition into the gel state around 25 C,
and G’ and G” values close to 10 kPa and 1 kPa, respectively. In vitro release studies
were performed using bovine serum albumin (BSA) as a model drug. It was noted by the
researchers that the release of BSA from the PF/GAG gel exhibited a slower burst than
other Pluronic based gels. It was hypothesized that the presence of GAGs allowed for the
slowed release of the BSA protein, due to the affinity between the two molecules. A
variety of different gels with Pluronic 127 and GAGs were tested for their effects on cell
viability, and none of them showed significant toxicity. Furthermore, hydrogels made
from PF/GAG resulted in better recovery of cartilage damage when injected into the
joints of rats, as compared to Pluronic gels without GAGs.
Not all recent examples of non-covalent hydrogels intended for IA use are thermally
responsive systems. In 2018 Joshi et al. performed a study using triglycerol monostearate
(TG-18) to create a self-assembling hydrogel, that was capable of encapsulating the
steroid triamcinolone acetonide (TA).162 Here, the hydrogel components were dissolved
in dimethyl sulfoxide (DMSO) at 55-60 C. Upon cooling of the solution, the TG-18 selfassembled into a hydrogel with fibrous structures that had interdigitated bilayers and
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extended micelles. The researchers showed that it was possible to load up to 40 w/w% of
TA into the hydrogel. Rheological and mechanical properties were not assessed as part of
this study, but the release of TA in response to an enzymatic stimuli of MMP inhibitors
was measured. The gel in PBS showed a prolonged release, with less than 35% of the
loaded cargo being released over 30 days. The gels were determined to be stimuli
responsive, increasing their release when fresh enzyme was added to the gel. MTT
assays, as well as LIVE/DEAD assays, were used to study the cytocompatibility in vitro;
metabolic activity did not drop lower than 65% across all time points for the cells treated
with the TG-18 hydrogel and LIVE/DEAD staining did not show any significant changes
in the viability of the cells. In vivo work was performed, and it was found that mice
treated with the TG-18 hydrogel and had lower clinical scores related to OA progression
than animals treated with gel having no drug, or no gel at all. The tests also demonstrated
that the system was able to respond to flares in vitro; inflammatory flares were modeled
through the addition of esterase to the release media, causing spikes in release.
In order to create strong, robust hydrogels that can withstand the mechanical forces in the
joint after IA injection, covalent crosslinking has been studied. Gels that use covalent
crosslinking mechanisms tend to have increased stiffness and strength relative to noncovalent gels, and also have the ability to encapsulate drug within their network. In
addition, they may have the added benefit of a slower degradation time, and therefore a
slower release time in the joint.
In 2019, Prince et al. studied a modification of the above described non-covalently linked
PCLA-PEG-PCLA hydrogels.158 The gels were synthesized using the previously reported
synthetic method, but methacrylate groups were added as endcaps, which could be
chemically crosslinked using potassium persulfate (KPS) and tetramethylethylenediamine
(TEMED) as a catalyst/initiator system.163 The covalent crosslinking of the hydrogel had
profound effects on the gelation, which was rapidly induced by the addition of
KPS/TEMED and increasing the temperature to 37 C. The G’ of the hydrogel was 7.7
kPa 1.2 after 60 minutes, while the compressive modulus was 19 kPa. Both of these
values were large increases compared to the previously measured G’ and compressive
moduli of the non-covalently crosslinked gels that were prepared from similar
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copolymers with acetyl end-caps. The release of celecoxib from these hydrogels was
measured in vitro and in vivo. After 30 days, only 20% of the loaded cargo had been
released from the hydrogel in vitro. In a horse model, celecoxib was detectable for up to
60 days, and was at a therapeutic level (above 1 g/mL) for 30 days. Despite the
increased mechanical integrity of the covalently-linked hydrogel, animals tolerated the
system well, with no adverse reactions noted in the study.
Similar to their use in non-covalently crosslinked systems, natural polymers have been
used in chemically crosslinked systems as well. One such example was studied by Lu et
al. in 2019.164 Here, a hydrogel was composed of HA, fucoidan and gelatin, and was
crosslinked chemically using the natural fruit extract genipin. All hydrogels that were
prepared using genipin as a crosslinking agent showed relatively high compressive
moduli, above 7 kPa, with the HA containing hydrogel having the highest modulus of
11.4 kPa. Gelation, as measured by rheometry, was found to occur after about 20
minutes. No cytotoxicity was observed when chondrocytes were treated with the
hydrogel, and the release of a loaded growth factor occurred over 15 days.
In some instances, work has been performed to study the effects of injecting hydrogels to
serve as a therapy, rather than encapsulating a drug. In 2017, von Lospichl et al. studied
the rheological properties of a degradable dendritic polyglycerol sulfate (DPGS) hydrogel
(Figure 1.11), that was designed to mimic the viscoelastic and mechanical properties of
HA when used in an IA injection.165 The covalent network of DPGS was hypothesized to
have similar properties to HA, but with the added benefit of a covalent crosslinking
mechanism, allowing for longer joint retention time. The G’ values of the DPGS
hydrogel were found to be very similar to those of commercially available HA injections,
and it was elucidated that at certain concentrations DPGS could be used as an alternative
to HA for viscosupplementation.
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Figure 0.11: Chemical structure of DPGS and hydrogel formation. Reproduced with
permission from reference 162. Copyright 2017, Elsevier.
The work that has been performed on IA hydrogels has moved treatment ahead, but the
challenge of prolonging the release from hydrogels still remains. It is well documented
that even when drugs are loaded within a hydrogel, they are subject to diffusion of the
drug, which can lower the efficacy of an IA hydrogel, even if it has a long joint residence
time. The desire to overcome the rapid diffusion of drug from hydrogels, and increase the
release time of drug after IA injection has led to new hydrogels that combine
technologies, or utilize new mechanisms to slow drug release.
In 2017, Stalder et al. researched the incorporation of liposomes within a hydrogel
matrix.166 Here, a dextran was used to make the hydrogel, and relied on in situ gelation
post injection. The study examined the effect of different linkages of the liposomes to the
hydrogel, and compared covalently bound liposomes to ones that were simply physically
entrapped. It was found through dynamic mechanical loading that by covalently linking
liposomes to the hydrogel, the release rate of the loaded cargo was lowered by 50%, and
after 200 cycles of loading, only 5% of the loaded dye had been released. Despite the
differences in linkages to the liposomes, all the hydrogels showed the same modulus of 1
kPa.
Furthermore, the ability to enhance the mechanical integrity of hydrogels through
different linkage strategies has been studied. Here, the goal is to develop hydrogels that
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are strong enough to withstand mechanical forces, and therefore will not release drug as
quickly. Zhang et al. studied a dual physically crosslinked gel that employed both
hydrophobic associations as well as ionic interactions.167 The tensile strengths of these
materials were measured and found to be between 150 and 300 kPa, making them some
of the strongest hydrogel materials that have been developed for biomedical applications
to date. However, the formulations were always in a gel state, and the development of
injectable versions would require further research.
The challenge to effectively deliver medications directly to the area of injury for OA
treatment remains. While hydrogel drug delivery systems have become excellent avenues
for the administration and delivery of drugs, the challenges of resident joint time, rapid
diffusion of drugs from the gel networks, and bioavailability of the drug still persist. The
use of covalent linkages has led to stronger hydrogel networks, that are capable of having
the long resident joint time required, but in many cases a rapid release of drug was still
noted, thereby lowering the likelihood of any loaded drug molecule imparting the target
biological effects prior to clearance.

Project overview
To date, a number of different disease modifying agents for OA have been proposed, yet
there is still no clinically available disease modifying agent. Previous work in the Beier
lab implicated PPARδ as a potential therapeutic target for a disease modifying agent in
OA. However, due to the likelihood of negative systemic side effects that could develop
from the result of oral or subcutaneous delivery, a suitable drug delivery system would
need to be prepared so that GSK3787 could be encapsulated, and released directly into
the joint over a time period of months. A number of IA drug delivery systems with the
goal of hydrophobic drug delivery have been studied to date, but no perfect system exists.
IA drug delivery systems are still limited by their poor mechanical integrity, leading to a
rapid breakdown in the joint, as well as burst release of drug after injection. Particles are
a commonly used for IA delivery due to their injectability and relatively favorable release
properties. Many other groups have reported on particle platforms made from synthetic
polyesters, such as PLGA, or PLA. Here, we propose the use of PEAs,145, 168-170 which are

41

attractive because of their tunable properties171 and the fact that they are well tolerated by
cells.172
The development of a platform delivery system is hallmarked by the ability to alter the
types, or amounts of medications that can be delivered using it, while only making minor
alterations to the formulation of the drug delivery system. Here, we experiment first on
the development of drug delivery systems designed to encapsulate and deliver the NSAID
celecoxib. This drug was chosen due to its common use in OA treatment, as well as
continued desires for increased celecoxib use in horses. It has been shown to be effective
for the treatment of the disease in animals, despite well documented side effects, so a
local delivery system could be beneficial. In addition, it is inexpensive and readily
available, allowing for extensive experimentation and characterization using techniques
that require large amounts of material. An initial delivery system developed for celecoxib
should be applicable to GSK3787.
Hydrogels have been commonly used as well for IA delivery, and remain an attractive
option for IA use as they can often be formulated as injectable liquids. Furthermore,
hydrogels have no history of causing mechanical irritation within the joint postadministration. Prolonging the release of drug from the hydrogel matrix after it has been
injected remains a goal for the development of new hydrogel formulations.
Overall, the goal of this thesis work is to develop new platform drug delivery systems
that can encapsulate GSK3787, as well as other medications, and provide a prolonged
release after injection into the joint.

1.10.1

Hypothesis

Poly(ester amide)s can be used to develop an intra-articular drug delivery system capable
of encapsulating and releasing GSK3787 and celecoxib in a controlled manner. Particles
prepared with poly(ester amide) will exhibit no cellular toxicity, and no measurable host
response when injected into animal models.
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1.10.2

Specific Aims

Objective 1: To compare two different PEAs for the preparation of particle-based
delivery systems for celecoxib and to evaluate the systems based on physiochemical
characteristics, toxicity on cells, and host response in vivo.
Objective 2: To use the results from objective 1, to develop and study PEA particles
loaded with the potential OA therapeutic GSK3787.
Objective 3: To develop a PEA particle-loaded thermo-responsive and covalently
crosslinked hydrogels to encapsulate and deliver GSK3787, and to evaluate the effect
of particle incorporation on the physicochemical properties of the hydrogels.
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Introduction
Osteoarthritis (OA) is a leading cause of mobility impairment and disability among adults
worldwide.1 The disease is prevalent in older generations, but the number and prevalence
continues to rise in younger populations as well.2 Although there are a number of
potential treatments under development, there are few clinically approved therapies.
Physical therapy and lifestyle changes are often first steps in treatment,3 followed by the
use of non-steroidal anti-inflammatory drugs (NSAIDs) to treat mild-to-moderate
musculoskeletal pain.4 However, systemically administered NSAIDs suffer from poor
distribution to joints and significant side effects including gastrointestinal problems and
cardiovascular risks. For example, celecoxib (CXB) is an NSAID that was approved for
use in OA treatment in the late 1990s.5 It is a potent cyclooxygenase-2 inhibitor that
blocks the production of prostaglandins and attenuates the inflammatory and pain
responses that are associated with OA. However, its side effects have become apparent
recently, and arise in part due to the high plasma concentrations required to provide
relief from OA symptoms.5,6 The intra-articular injection of the drug using a delivery
system can potentially lead to a higher delivered dose while minimizing the side effects
to off-target tissues by reducing systemic drug levels.7
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Several different classes of drug delivery systems have been studied for intra-articular use
including hydrogels,8 nanoparticles,9, 10 and crystalline drug formations.11 Although each
of these systems has different structures and properties, they are all designed to release
the drug over prolonged periods after injection into the joint without adverse reactions of
the joint tissue to the delivery platform. Polymer particles are promising drug delivery
systems due to their tunable properties, ease of preparation, and potential for prolonged
drug release.12 A wide variety of different polymers can be used, and the size and
degradation rates of the particles can be controlled.13, 14 Poly(ester amide)s (PEAs) are
degradable polymers containing both ester and amide linkages in their backbones.15, 16
Their thermal and mechanical properties as well as their degradation rates can be readily
tuned through the incorporation of different monomers such as amino acids, diols, and
dicarboxylic acids.17, 18 PEAs have shown favorable properties as potential drug delivery
systems when formulated as micelles19 or microparticles.20-22 They have also been shown
to support the growth of cells23-25 and to exhibit good biocompatibility when studied in
vivo.26, 27 Thus far, there are very few examples involving the use of PEAs for intraarticular drug delivery. In one study, PEA particles were shown to release CXB in
response to inflammation,21 while in another study they were demonstrated to release
triamcinolone.22 In each case, the particles were shown to exhibit sustained drug release
and retention in rat joints with good host response. However, there are many different
structures of PEAs with different properties that remain uninvestigated to date.
We describe here the comparative study of particles composed of two different PEAs –
one composed of phenylalanine, 1,4-butanediol, and sebacic acid (PBSe) and the other
composed of phenylalanine, 1,8-octanediol, and sebacic acid (POSe). This simple change
in the diol component leads to different properties for the two polymers. The thermal and
mechanical properties of the polymers with and without CXB were studied. The drug
release rates and in vitro toxicity studies of the particles were evaluated. In addition, host
response to the PEA particles was evaluated in a large animal (ovine) model.
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Materials and Methods
2.2.1

General materials and procedures

PBSe and POSe were synthesized and characterized as previously reported.24 Poly(vinyl
alcohol) (PVA) and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) were purchased from Millipore-Sigma (Oakville, ON). CXB was obtained from
Ontario Chemicals Inc. (Guelph, ON). Dynamic light scattering was performed with a
Zetasizer NanoZS from Malvern Instruments at 24.5 C. The Z-average diameter and
polydispersity index (PDI) for each type of particle were measured for three different
batches. Differential scanning calorimetry (DSC) was performed on a Q2000 from TA
instruments (New Castle, DE). The heating/cooling rate was 10 C/min from 0 to +180
C, and the data were obtained from the second heating cycle. Statistical analyses were
performed by one way ANOVA (Microsoft Excel, 2016) with alpha set at 0.05, followed
by a Bonferroni post-hoc analysis, when applicable.

2.2.2

Tensile testing

Polymer samples, either pure or mixed with 30 wt% CXB (mixing was performed by codissolution of drug and polymer in CH2Cl2 followed by solvent evaporation), were
prepared by melt pressing the polymer at 200 C, and then cutting the resulting sheet into
rectangular bars with dimensions of 25 mm  10 mm  1 mm (accurately measured with
calipers). Tensile testing was performed on a CellScale Univert (Guelph, ON), in
phosphate buffered saline (PBS) at 37 C using a 10 N load cell. Samples were pulled at
a rate of 2.5 mm/min for 240 seconds. Testing was performed on three separate samples
of hydrogel (at minimum) for each system.

2.2.3

Contact angle measurements

Solutions were prepared by dissolving either pure polymer or polymer with 30 wt% CXB
in CH2Cl2 and then filtering the solution through a 0.2 µm filter. The solution was then
added dropwise onto a silicon wafer until it was completely covered. The wafer was then
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spun at 1000 rpm for 1 min. The static water contact angles of the resulting films were
then measured using 10 µL drops of deionized water with a Kruss DSA100 Drop Shape
Analyzer (Hamburg, Germany). The drop was measured after 10 s of being on the
surface. Three measurements were taken for each of the samples.

2.2.4

Preparation of particles

Particles were prepared using an oil-in-water emulsion evaporation technique. The
dispersed phase of the emulsion was prepared by dissolving 400 mg of polymer in 200
mL of CH2Cl2. For CXB-loaded particles, 175 mg of CXB was also added to the CH2Cl2
phase. The continuous aqueous phase was prepared by dissolving 5 g of PVA in 1 L of
deionized water. The emulsion was made by slowly pouring the dispersed phase into the
continuous phase, while stirring using a Waring Commercial immersion blender, set to
low (~9000 rpm). The emulsion was mixed at 9000 rpm for an additional 2 min, then
transferred to a 1 L beaker, and the organic solvent was evaporated under constant
stirring overnight. Particles were collected the next day by centrifugation at 2800 g for 10
min and were then lyophilized. The dried samples were stored at 4 C until use.

2.2.5

Scanning electron microscopy (SEM)

SEM was performed in the University of Western Ontario’s Nanofabrication Facility
using a LEO 1530 instrument, operating at 2.0 kV and a working distance of 6 mm.
Samples were mounted on stubs covered in carbon tape and coated with osmium using a
SPI Supplies, OC-60A plasma coater. Particles in three different images and three
representative sections (~30  30 m) per image were measured to calculate the average
diameters  standard deviation.

2.2.6

Determination of drug loading and encapsulation efficiency

10 mg of dried particles were dissolved in 1 mL of deuterated dimethyl sulfoxide and 1H
NMR spectra were obtained at 400 MHz on a Bruker 400 NMR Spectrometer (Bruker
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Instruments, Milton, ON). Integration values of peaks for PEA, PVA and CXB were used
to calculate the percentage of each, as seen in Appendix A, Figure A.7. Calculation was
performed by first integrating the peaks at 2.8-3.0, corresponding to the four benzylic
protons on the phenylalanine units of the PEA. These peaks were set to 4.0,
corresponding to one repeat unit of PBSe (molar mass of repeat unit = 550.7 g/mol). The
peak at 7.55 ppm was integrated corresponding to four protons on CXB. (molar mass of
CXB = 381.4 g/mol). The peak at 3.85 ppm corresponding to PVA was integrated, and
corresponds to 0.83 protons per repeat unit of PVA (note that the integration is not 1.0 as
the PVA is partially acetylated) (molar mass of PVA repeat unit = 44.1 g/mol). Drug
loading (DL) and encapsulation efficiency (EE) were then calculated according to
equations (1) and (2).
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
) 𝑥 100 (1)
% 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 = (
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
% 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
=(

2.2.7

𝐴𝑐𝑡𝑢𝑎𝑙 𝐶𝑋𝐵: 𝑃𝐸𝐴 𝑚𝑎𝑠𝑠 𝑟𝑎𝑡𝑖𝑜
) 𝑥 100 (2)
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑥. 𝐶𝑋𝐵: 𝑃𝐸𝐴 𝑚𝑎𝑠𝑠 𝑟𝑎𝑡𝑖𝑜

In vitro release of CXB

300 mg of particles were suspended in 5 mL of pH 7.4 phosphate buffered saline (PBS)
containing 2 wt% Tween 20. The suspension was dialyzed at 37 C using a 10 kDa
molecular weight cut-off dialysis membrane against 350 mL of PBS containing 2 wt%
Tween 20. Aliquots (2 mL) of the dialysate were taken daily for 20 days, and then every
5 days for up to 60 days to measure the CXB released from the particles. The amount of
released drug in the dialysate was quantified using UV-visible spectroscopy at a
wavelength of 253 nm based on an extinction coefficient of coefficient of 1.65  104
L·mol-1·cm-1 for CXB in the same buffer system. All removed aliquots were replaced
with PBS containing 2 wt% Tween 20. Furthermore, the dialysate was replaced
completely when absorbance values were higher than 0.8. The experiment was performed
on triplicate samples.
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2.2.8

In vitro degradation of particles in PBS

The particles were incubated in PBS at 37 C and were removed after 7, 14, 30 and 60
days. Once removed, the samples were washed once with deionized water then
lyophilized and imaged by SEM as described above.

2.2.9

Cell culture

ATDC5 and C2C12 cells were thawed and cultured as previously described.28, 29
Reagents were purchased from Sigma Aldrich (Oakville, ON). ATDC5 cells were grown
in culture medium containing 225 mL of Dulbecco’s Modified Eagle’s Medium (DMEM)
and 225 mL F12 media with the addition of 10 mL of penicillin-streptomycin (1000
units/mL), 5 mL of L-Glutamine (200 mM) and 50 mL of Fetal Bovine Serum (FBS).
C2C12 cells were grown in medium comprising 500 mL of DMEM supplemented with
10 mL of penicillin-streptomycin (1000 units/ mL), 5 mL of L-Glutamine (200 mM) and
50 mL of FBS. Cells were cultured at 37 C in an incubator with 5% CO2. ATDC5 cells
were induced to differentiate into chondrocytes with 1% Insulin-Transferrin-Selenium
(ITS) in DMEM prior to experimentation

2.2.10

In vitro toxicity

Cells were seeded at a density of 5000 cells per well in a 96-well plate and incubated for
24 h prior to treatment. Varying concentrations of particles (0.025 -1.0 mg/mL) or free
CXB (5-100 g/mL) were suspended in cell culture media and added to the cells. Media
alone was used as a negative control, and sodium dodecyl sulfate (SDS) was used as a
positive control. After 48 h, the medium was aspirated and replaced with 100 µL of fresh
medium containing 0.5 mg/mL of MTT reagent and allowed to react for 4 h in the
incubator. After 4 h the plate was removed and the MTT reagent solution was aspirated.
50 µL of dimethyl sulfoxide was added to each well to solubilize the purple crystals. The
plate was then placed in a plate reader (Tecan Infinite M1000 Pro) and the absorbance at
540 nm was measured to quantify the relative metabolic activities of the cells. Four
biological replicates were performed, as well as six technical replicates per plate.
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2.2.11

In vivo host response

All procedures were done in compliance with the guidelines of The Canadian Council on
Animal Care guidelines (University of Guelph Protocol 3974). An ovine model was used
to test the in vivo host response of the particles. Intra-articular injections of 50 mg of
PBSe-CXB particles suspended in 1 mL of sterile saline were made into one knee
(femoropatellar) joint of four sheep. Sheep were monitored daily for lameness, joint
effusion, periarticular swelling, fever, and heart rate. Synovial fluid samples and plasma
samples were collected under sedation at day 0, 8, and 15 days to measure leucocyte
concentration using a solid state chip cytometer according to the manufacturer’s
instructions (Orflo Technologies, Ketchum, ID) and total protein content using a
Goldberg refractometer.30 Two animals were sacrificed on day 8 and two on day 15.
After macroscopic assessments of the joint space, synovial membrane samples were
harvested, fixed in 10% buffered formalin, and embedded in paraffin to create 5 M
histological sections that were stained with a hematoxylin and eosin (H&E) stain.

Results
2.3.1

Particle preparation and characterization

The PEAs PBSe and POSe (Figure 2.1) were synthesized as previously reported and were
characterized by 1H NMR spectroscopy, size exclusion chromatography, and DSC
(Figures A.1-A.4).24 The batch of PBSe used in the current work had a number average
molar mass (Mn) of 30 kg/mol and dispersity (Đ) of 2.0 while POSe had an Mn of 18
kg/mol and a D = 1.9. PBSe had a glass transition temperature (Tg) of 34 C, while POSe
had a Tg of 14 C and a melting temperatures (Tm) of 106 and 150 C. Using these PEAs,
four different types of particles were prepared: non-drug-loaded PBSe (PBSe-NDL), nondrug-loaded POSe (POSe-NDL), CXB-loaded PBSe (PBSe-CXB) and CXB-loaded POse
(POSe-CXB). The average particle size was determined using the SEM and DLS (Figure
2.2, Table 2.1). Based on DLS, PBSe-NDL had a Z-average diameter of 790  64 nm,
which was not statistically significantly different from PBSe-CXB with a Z-average
diameter of 836  51 nm (p = 0.56). In contrast, both POSe-NDL and POSe-CXB were
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smaller with Z-average diameters of 487  10 nm and 398  13 nm, respectively, and
were statistically significantly different from one another (p = 0.02). SEM confirmed that
the particles were all spherical. The diameters measured by SEM were generally larger
than those obtained by DLS, but the trends were similar, with both POSe-based particles
being statistically smaller than their PBSe counterparts (p = 0.03). Based on SEM, neither
PBSe or POSe exhibited a significant change in diameter when loaded with CXB (p =
0.09). The drug loading was 23 wt% for PBSe particles, and 20% for POSe, with
encapsulation efficiencies of 84 and 69%, respectively.

Figure 2.1: Chemical structures of the polymers PBSe and POSe.
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Figure 2.2 Size and Morphology of Celecoxib particles. A) DLS diameter distributions
by volume % for CXB and non-drug-loaded particles made from either PBSe or POSe;
B-E) SEM micrographs of prepared particles showing their spherical structures and size
distributions: B) PBSe-NDL; C) PBSe-CXB; D) POSe-NDL; E) POSe-CXB. Material
surrounding the particles in B and D is likely PVA.
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Table 2.1: Average diameters of the PEA-based particles obtained by DLS and SEM
and CXB loading and encapsulation efficiency measured by NMR spectroscopy.
Errors correspond to the standard deviations on triplicate measurements of three different
particle compositions.
Particle

Z-Average

Measured

CXB

CXB

Composition

diameter

particle

loading

encapsulation

(DLS) (nM)

diameter (SEM)
(nM)

efficiency (%)
(wt%)

PBSe-NDL

790  64

870  74

-

-

PBSe-CXB

836  51

1040  100

23  1

84  4

POSe-NDL

487  10

867  92

-

-

POSe-CXB

398  13

637  101

20  4

69  15

DSC was used to investigate the effects of 30 wt% CXB incorporation on the thermal
properties of the bulk polymers (Appendix A, Figure A.5). For PBSe, incorporation of
CXB resulted in glass transitions at 31 and 45 C, while for POSe it resulted in
disappearance of crystallinity and an increase in the Tg to 29 C. DSC was also
performed on the particles (Figure 2.3). PBSe-NDL had a Tg of 38 C while POSe-NDL
had a Tg of 30 C. The addition of CXB to the particles resulted in a small increase in Tg
for PBSe-CXB to 41 C, but no change for POSe-CXB. No melting point for CXB was
observed.
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Figure 2.3 DSC thermograms of drug-loaded and non-drug-loaded particles. DSC
traces showing that the Tg was increased through CXB incorporation only for PBSe. A
subtle transition corresponding to PVA was observed at 60 – 70 °C but no melting
temperature was observed for CXB.
Tensile testing of PBSe and POSe as well as their blends with and without 30 wt% CXB
was performed in water at 37 C. POSe had the highest Young’s modulus of 26  16
MPa, while PBSe had a modulus of 1.17  0.19 MPa (Table 2.2). The addition of CXB to
the polymers decreased the Young’s moduli to 0.43  0.15 MPa and 0.83  0.68 MPa for
POSe-CXB and PBSe-CXB, respectively. Contact angle measurements were performed
to compare the hydrophobicities of the polymers and their blends with CXB in the form
of thin films (Table 2.2). PBSe was more hydrophilic, having a contact angle of 77.4 
0.9 , compared to POSe having a contact angle of 85.3  1.7 . The incorporation of
CXB significantly increased the hydrophilicity in each case, lowing the contact angle to
72.3  0.8  for PBSe-CXB and 79.2  0.1  for POSe-CXB.
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Table 2.2: Young’s moduli and ultimate tensile strengths of the polymers and their
blends with CXB, as measured by tensile testing in water at 37 ºC and contact angles
of polymer films. Errors on the measurements correspond to the standard deviations of
triplicate samples.
Polymer

Young’s modulus

Ultimate Tensile

Composition

(MPa)

Strength (MPa)

PBSe-NDL

1.17  0.19

0.66  0.3

77.4  0.9

PBSe-CXB

0.83  0.68

0.04  0.01

72.3  0.8

POSe-NDL

26  16

5.6  2.2

85.3  1.7

POSe-CXB

0.43  0.15

0.16  0.04

79.2  0.1

2.3.2

Contact angle ()

In vitro release of CXB and particle degradation

The release of CXB from PBSe-CXB and POSe-CXB particles was determined through
dialysis and detection of the CXB in the dialysate. Both particle systems exhibited a
slower release than free CXB, which was used as a control (Figure 2.4). PBSe-CXB had a
slower release than POSe-CXB. At 40 days, 25% of the loaded CXB had been released
from PBSe-CXB, while 70% had already been released from the POSe-CXB. The
degradation of particles in pH 7.4 PBS at 37 C over time was probed by SEM. PBSeCXB particles showed a distinct surface degradation at all time points, with increased
degradation over time (Figure 2.5A-C). However, particles were still visible at day 60.
POSe-CXB underwent more rapid degradation, with the loss of most particles apparent
by 7 and 14 days (Figure 2.5 D-E).
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Figure 2.4: CXB release from PBSe-CXB particles and POSe-CXB particles
performed in pH 7.4 PBS containing 2 wt% Tween 20 showing slower release of CXB
from the PBSe-CXB particles. The release of insoluble free CXB through the dialysis
membrane was also measured as a control to show that the release rate was not limited by
the drug dissolution rate.
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Figure 2.5: Degradation of PEA particles in pH 7.4 PBS at 37 C. A-C) PBSe-CXB
particles after A) 14, B) 30 and C) 60 days; D-E) POSe-CXB particles after D) 7 and E)
14 days. All images were obtained at the same magnification. While particles were still
observed for PBSE-CXB at 60 days, most of the POSe-CXB particles were rapidly
eroded.

2.3.3

In vitro and in vivo studies

Based on their CXB release and degradation properties, PBSe particles were evaluated
using MTT assays in two different cell lines – mouse cartilage-like ATDC5 cells and
mouse myoblasts C2C12. After 48 h of incubation with PBSe-NDL particles both cell
lines retained high metabolic activity at all concentrations evaluated, up to 1 mg/mL
(Figure 2.8), as measured by MTT activity. In contrast, PBSe-CXB particles exhibited
concentration dependent decreases in metabolic activity for both cell lines, with a 50%
reduction at ~0.1 mg/mL. Free CXB also exhibited concentration-dependent toxicity with
a 50% reduction in metabolic activity of ATDC5 and C2C12 cells at ~20 g/mL and 40
g/mL, respectively (Figures 2.6-2.7).
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Figure 2.6: Metabolic activity of ATDC5 cells as treated with increasing
concentrations of CXB. As measured by MTT assay. Metabolic activity reported as an
average percentage of control cells (mean  SD), N=4.

Figure 2.7 Metabolic activity of C2C12 cells as treated with increasing
concentrations of CXB. As measured by MTT assay. Metabolic activity reported as an
average percentage of control cells (mean  SD), N=4.
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Figure 2.8: Metabolic activity of cells treated with particles. A) ATDC5 cells and B)
C2C12 cells as measured by an MTT assay after a 48 h incubation with PBSe-CXB or
PBSe-NDL particles. Reported as mean  SD. (N = 4).
After intra-articular injections of PBSe-CXB (50 mg particles in 1 mL of saline) in sheep,
there was minimal effusion for 48 hours, but no lameness, fever, changes in eating habits,
or changes in social interactions were observed. Synovial fluid analysis showed a small
but significant increase in both white blood cells (WBC) and total protein concentrations
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post injection (Figure 2.9). Histological analysis showed mild synovial intimal
hyperplasia, with some increase in vascularity but no cellular infiltration. Specifically, the
particles could be identified in the synovial lining and subintimal layer, but there was no
presence of macrophages noted. (Figure 2.10).

Figure 2.9: Synovial fluid analysis of injected sheep joints. A) Protein levels in
synovial fluid at days 0, 8 and 15. * Indicates a significant difference between day 0 and
day 8. (ANOVA p = 0.04) B) WBC levels at days 0, 8 and 15. * Indicates a statistically
significant difference between day 0 and day 8 (ANOVA p = 0.0001). N = 4 at days 0
and 8 and N = 2 at day 15.
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Figure 2.10: Immunohistochemical analysis of the synovial membrane of an injected
sheep 15 days post injection. Hematoxylin and eosin staining was performed on sections
of sheep synovium. Particles are visible within the membrane (indicated with red
arrows).

Discussion
A wide variety of PEAs having different structures and properties have been previously
reported.15, 16 For the current work, PBSe and POSe were selected as they are easily
synthesized, and have shown promising biological properties such as high cell
compatibility in previous work.23, 24 Furthermore, polymerizations that result in PBSe and
POSe are easily scalable, allowing a large amount of bulk polymer to prepare particles
from. In addition, despite the minor structural difference of containing butyl versus octyl
chains in their backbones, they have been shown to exhibit different thermal and
mechanical properties.31 The Tg value of 34 C for the bulk PBSe used in the current
work was similar to those previously reported for this polymer (38 – 40 C).24, 31 POSe
was semicrystalline in the bulk state with Tm values of 106 and 150 C similar to those
previously reported.24, 31 However, the Tg of 14 C measured for POSe was significantly
lower than that previously reported (22 – 28 C), which can likely be attributed to its
lower molar mass (Mn of 18 kg/mol for current versus 30 – 78 kg/mol previously).
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Prior to the preparation of particles, a large number of studies were performed, in which
the variation of a number of parameters were tested for their effect on resultant particles.
Surfactant amount, mixing methods, polymer concentration, and mixing methods were all
varied, and their resultant effects on particles were examined by DLS and SEM. CH2Cl2
CH2Cl2 was selected as the organic solvent for the emulsification-evaporation particle
preparation because it is a good solvent for both PEA and CXB and is immiscible with
water, as required for the process. In contrast to previously reported work on PEA
particles, the use of CH2Cl2 did not lead to particles of irregular shape.20 This may result
from different parameters such as solvent ratios, mixing time and evaporation time used
in the current work.32 We fixed the PEA concentration at 2 mg/mL because of solubility
limitations. In addition, we fixed the water:CH2Cl2 at 5:1 mL based on previous work.20
Different emulsification processes were explored and an immersion blender operating at
9000 rpm proved to be the best, whereas a magnetic stir bar led to large conglomerates of
material in addition to spherical particles and sonication appeared to result in breakdown
of particles. 5 wt% PVA in the water was the most appropriate concentration as lower
concentrations led to insufficient particle stabilization and consequent agglomeration,
whereas higher concentrations led to particles that were immersed in a large excess of
PVA and were difficult to purify.
It has been suggested that particles of different sizes have different advantages and
limitations in the context of intra-articular drug delivery. The size of synthesized particles
was consistent with what is believed to be suitable for intra-articular delivery. With a
diameter of 500-1000 nm, it is expected that particles will be small enough to not induce
a significant immune response, but large enough to have a long residence time in the
joint, and not be rapidly cleared.33 The diameters measured by DLS were consistently
smaller than those measured by SEM across all samples. While larger particles are often
emphasized in DLS measurements due to their increased scattering of light relative to
smaller particles, in this case it is likely that the larger particles settled during the
measurement and were thus not completely captured in the size distribution. POSe
particles were significantly smaller than the PBSe particles in both their CXB-loaded and
non-loaded forms. However, a small fraction of larger (>1000 nm) particles was detected
for POSe-NDL by both DLS and SEM. As supported by the contact angle
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measurements, POSe is more hydrophobic, owing to the increased length of the diol
component. This may make these particles more difficult to disperse, while at the same
time favoring interactions with the PVA surfactant, which may lead to the stabilization of
smaller particles. It was also notable that the incorporation of CXB produced particles
with higher purity (less surrounding material) in the case of both POSe-CXB and PBSeCXB. As previously reported, it was expected that the CXB could play the role of a
surfactant, which could further stabilize the emulsion and allow for morphologicallyoptimized particles.34
High drug loading contents and acceptable encapsulation efficiencies were achieved for
both the PBSe and POSe particles. High hydrophobicity of CXB results in its preferential
partition into the organic phase, thereby resulting in its encapsulation rather than loss into
the aqueous phase. The high drug content achievable also suggests high compatibility of
CXB with the PEAs used here. It is notable that the drug content of our particles was
much higher than the 5 wt% CXB reported by Janssen et. al in different PEA particles.21
Higher drug content is desirable to minimize the dose of polymer required to administer a
given quantity of drug. It was found that the drug loading percentage that was achieved in
this study was the maximum amount that was able to be loaded without sacrificing
particle integrity. A high amount of drug in particles was desired due to the desired
prolonged release model that the particles were intended to be used for.
In comparing the thermal properties of the bulk polymers to those of the particles both
with and without CXB, PBSe-NDL particles had a slightly higher Tg of 38 C compared
to 34 C for the bulk polymer. A secondary Tg was observed at 60-70 C for all of the
particles, which likely corresponds to the PVA coating the particles and it is possible that
some incorporation of PVA into the particles modestly increased the Tg. The
incorporation of CXB into the PBSe particles increased the Tg by 3 C, suggesting that
interactions between CXB and PBSe decreased the mobility of the polymer. The
incorporation of CXB into bulk PBSe resulted in a main Tg value of 31 and a small
secondary Tg of 45 C, suggesting the presence of small CXB-rich domains due to some
degree of phase separation. This phase separation may have been induced by the melt
pressing process, but it was deemed important to process the samples in the same way as
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for the tensile testing samples in order to correlate their properties. While POSe in the
bulk state was semicrystalline, no Tm was observed for POSe particles and instead a
single Tg value of 30 C was observed. This result highlights the importance of the
processing conditions on the properties of the polymers. While the incorporation of CXB
into the POSe particles did not affect their Tg, the incorporation of CXB into bulk POSe
resulted in complete loss of crystallinity and a single Tg value of 29 C, a result that is
important for understanding the tensile properties of the samples. The thermal properties
of bulk POSe-CXB were consequently very similar to POSe-CXB particles. No melting
point for CXB was observed in the expected range (157-159 C) for any of the particles,
suggesting that CXB was mixed well with the PEAs.
The Young’s moduli and ultimate tensile strengths of melt pressed polymers and their
blends with CXB were explored. These tests were performed with the samples in a
hydrated state at 37 C to mimic physiological conditions, particularly because water is
known to have a significant plasticizing effect on amorphous polymers.35 Indeed,
increasing the temperature to 37 C immersed in water relative to ambient temperature in
the dry state lowered the Young’s modulus of PBSe from ~1 GPa to 1.17  0.19 MPa.31
The addition of CXB resulted in a further decrease in modulus to 0.83  0.68 MPa. The
decrease may correlate with the observed lowering of the main Tg for bulk PBSe-CXB
relative to PBSe. Consistent with a decreased water contact angle upon CXB
incorporation, it may also be attributed to CXB’s ability to hydrogen bond to water,
thereby enhancing interactions of the blends with water, further increasing the water
plasticization effect. This brings the modulus into a range similar to articular cartilage,36
which is desirable as the injection of high modulus materials into the joint may be
expected to cause irritation. Similar trends were observed for the ultimate tensile strength,
with immersion in water resulting in a ~30-fold decrease relative to the polymer in the
dry state at ambient temperature and CXB inducing a further decrease.31 POSe-NDL had
a higher Young’s modulus and higher tensile strength in water at 37 C, which likely
arises from its semi-crystallinity in the bulk, and would not likely be reflective of the
properties of the particles, which were not semicrystalline. However, upon incorporation
of CXB, POSe-CXB became completely amorphous, resulting in a decrease in the
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Young’s modulus to a value lower than that of PBSe-CXB. Plasticization by water may
play an additional role in decreasing the modulus as a decrease in water contact angle
was also observed for POSe upon CXB incorporation. The mechanical properties of the
bulk POSe-CXB should reflect those of the POSe-CXB particles as they had very similar
thermal properties. Overall, these results highlight the importance of small PEA structural
variations as well as processing conditions in controlling the properties of the polymers
under different conditions.
Due to CXB’s very low solubility in water, 2 wt% of the surfactant Tween 20 was added
to the dialysis release medium. A control experiment performed by the addition of
unencapsulated solid CXB into a dialysis bag showed that CXB dissolution and diffusion
through the dialysis bag was still quite slow with ~50% release after 10 days. However, it
was faster than for CXB loaded into PEA particles, confirming that particle encapsulation
was able to provide sustained release of drug due to rate-limiting release from the
particles. PBSe-CXB in particular showed very slow release of drug, with only 36%
released over 60 days. SEM images of the particles after 14, 30, and 60 days in PBS at 37
C supported that the slow release can likely be attributed to slow degradation of the
particles. The lack of burst release and ability of the PBSe particles to retain the drug
over a prolonged time period are favorable properties for an intra-articular delivery
system as it is desirable to maximize the time between required doses. On the other hand,
POSe-CXB exhibited a release rate of CXB that approached that of the free drug and
SEM images showed a rapid loss of particle structure even after 7-14 days. We attribute
this behavior to the low Tg of POSe-CXB in water, which may result in particle fusion
and reorganization, processes which are accompanied by the loss of CXB. It is also
possible that the lower molar mass of POSe compared to PBSe resulted in more rapid
polymer degradation.
PBSe particles were selected for biological studies due to their favorable CXB release
and degradation properties. Cytotoxicity studies were performed on ATDC5
“chondrocyte-like” cells and C2C12 myoblast cells. The use of two different cell lines
allows for the detection of cell line-dependent responses to the particles, and should
provide an indication of how different tissues might react to the particles. C2C12 was
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selected as it is a commonly used cell line for in vitro work. High metabolic activities
were retained for the PBSe-NDL particles in both cell lines at concentrations up to 1
mg/mL. This was expected as previous studies have shown that PBSe was well tolerated
by cells.23, 24 On the other hand, concentration-dependent toxicity was observed for
PBSe-CXB in both cell lines. This was expected as we observed significant toxicity of
free CXB on both cell lines at 20 – 40 g/mL and PBSe-CXB particles can release CXB
during the assay. It is also in agreement with previous studies, where CXB has been
showed to exhibit toxicity in vitro.37 Interestingly, ATDC5 cells never reached 100% of
the metabolic activity as compared to the control, even at low concentrations of PBSeNDL or PBSe-CXB. An initial drop in the metabolic activity could was noted in all
experiments, a phenomenon that was not seen in C2C12 cells, leading to the hypothesis
that the presence of particles interacted with the cells and could be limiting transport into
and out of the cell, thereby lowering the metabolic activity.
In vivo pilot studies were performed in an ovine model. This large animal model allowed
for a robust histological examination, and serial synovial fluid analysis. Intra-articular
injections were performed on 4 sheep, which was sufficient to provide an initial
indication of host response to the PBSe-CXB particles. A dose of 50 mg/animal was
selected in order to have the most possible CXB injected into the joint, while maintaining
the injectability of the drug delivery system. As reported by Janssen et al. for different
PEA particles, PBSe-CXB particles appeared to have been engulfed by synovial lining
cells and local macrophages, resulting in particles within the synovial villi.21 The mild
increase in vascularity and intimal lining cells is consistent with the trauma of synovial
fluid collection. The particles themselves appeared to be remarkably inert. White blood
cell and protein concentrations in the synovial fluid post injection did increase
significantly, but the increase was small and within the levels expected from
arthrocentesis alone. Overall, our observations were similar to those reported previously
following the injection of a CXB-containing hydrogel into horse joints.38
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Conclusions
Particles composed of two different PEAs were prepared and characterized. It was found
that small structural differences in the polymers led to significant changes in the particle
properties including their Tg values and Young’s moduli and also led to different CXB
release rates. The slower release profile of the PBSe-CXB particles makes them more
ideal for intra-articular drug delivery. PBSe-NDL particles were found to be well
tolerated by both ATDC5 and C2C12 cells, while the presence of CXB in the PBSe-CXB
particles induced concentration-dependent toxicity in both cells lines. Initial in vivo
results in an ovine model showed that the PBSe particles migrated to the synovial
membrane and surrounding tissue and were well tolerated at a dose of 50 mg/animal.
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Chapter 3

3

Preparation and Characterization of Poly(ester amide)
Particles Loaded with the PPAR Antagonist GSK3787
Introduction

Osteoarthritis (OA) is the most common joint disorder worldwide, and is a leading cause
of chronic pain and disability.1, 2 More than 242 million people worldwide suffer from
OA, at a cost between 1 and 2.5% of gross domestic product in developed countries.3 The
disease is multi-faceted, affecting numerous tissues within the joint, including cartilage,
bone and synovium. Exercise has been demonstrated to safely reduce pain and improve
physical function in OA patients.4,5 Nonsteroidal anti-inflammatory drugs (NSAIDs) can
also be used, but can lead to cardiovascular6 and gastrointestinal complications.7 Next
stage options include intra-articular injections of corticosteroids.8 Unfortunately, none of
the above treatments alter the progression of the disease.9 Joint replacement therapy can
be used for end stage disease, but is limited by risks of infection, the potential for implant
failure, and altered biomechanics which can lead to degenerative changes in other parts of
the body.10, 11 Thus, improved treatments that are capable of slowing or halting OA
progression are urgently needed.
In an effort to develop disease modifying treatments for OA, a greater emphasis
has been placed on understanding of the molecular mechanisms involved in OA.12
Recently, a number of targets have been identified. For example, inflammatory
modulators such as interleukins,13 or the NF-κB pathway14 have been identified as
potential targets. Ion channels, such as TRPV115 or voltage gated sodium channels, which
are associated with pain, have also been investigated.16 Recent research in our lab showed
that activation of peroxisome proliferator activator receptor (PPAR)  resulted in the
degradation of cartilage tissue in an explant culture model.17 In addition, cartilage
specific PPAR knockout mice were protected from post-traumatic OA (PTOA)
following a destabilizing medial meniscus surgery. PPAR antagonists have been
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previously developed. For example, GSK3787 was shown to have high selectivity for
PPAR receptor.18 However, PPAR has important roles throughout the body,
particularly in glucose and lipid metabolism,19-21 so the use of GSK3787 in a fashion that
would lead to high drug levels systemically would likely not be feasible due to the high
risk of side effects.
Localized delivery of drugs into the joints through intra-articular injection is
recognized as a promising approach for the administration of OA therapeutics as it allows
the drug to be delivered in the appropriate dose to the target tissue, while minimizing
systemic exposure, and therefore potential side effects.22 However, free drugs that are
injected into the joint are subject to rapid clearance by lymphatic drainage within a matter
of hours, thereby limiting their ability to achieve a therapeutic effect.23 Drug delivery
systems provide an opportunity to incorporate therapeutics into a material that can
provide sustained release into the joint.24 A number of drug delivery systems for intraarticular injection have been developed, including liposomes,25 particles,26-28 hydrogels,2931

and dendrimers.32 Particles in particular have been shown to afford prolonged release

in the joint over a period of months. For example, microparticles composed on
poly(lactic-co-glycolic acid) (PLGA) encapsulating the corticosteroid triamcinolone were
recently approved by the United States Food and Drug Administration.33
Poly(ester amide)s (PEAs) are an alternative class of biodegradable polymers to
polyesters. They have tunable thermal and mechanical properties,34 and often undergo
surface erosion rather than bulk degradation, enabling controlled drug release and
reduced concentrations of potentially inflammatory acidic species upon degradation.35, 36
Furthermore, PEAs have been shown to be well tolerated in joints,27, 28 and in other in
vitro37, 38 and in vivo39 applications. For example, PEAs have been utilized as cell
scaffolds for tissue regeneration purposes, and were found to support cell adhesion and
proliferation.40, 41 They have also been explored for their ability to encapsulate and
release cell growth factors and bactericides.42,43 PEA particles loaded with celecoxib were
shown to release the drug in response to inflammation and were well tolerated in a rat
model.27 They were also explored for the controlled release of triamcinolone.44 We
recently reported the preparation and study of celecoxib-loaded PEA particles and found
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that minor changes in PEA chemical structure led to large differences in the release rate
of the drug.28 The particles were also well tolerated in an ovine model. However, as noted
above, the delivery of NSAIDs or corticosteroids would not lead to disease-modifying
effects, so it is of interest to develop delivery systems that will enable the study of
potential disease-modifying therapies.
Here, we describe the incorporation of the PPAR antagonist GSK3787 to PEA
particles. The particles were prepared through an emulsification-evaporation method and
characterized by scanning electron microscopy (SEM), dynamic light scattering (DLS),
atomic force microscopy (AFM), and thermal analyses. The release rate of GSK3787 in
vitro was evaluated and the particles were tested for toxicity on primary immature murine
articular cartilage (IMAC) cells. Confocal microscopy was performed to examine the
interactions between the particles and cells. Tissue explant models were used to assess
the injectability of the drug delivery system, as well as the passive diffusion of particles
through tissue.

Materials and Methods
3.2.1

General materials and procedures

The PEA used in this work, referred to as PBSe, was composed of phenylalanine,
butanediol, and sebacic acid, and was synthesized and characterized as previously
reported.37 For this study, the batch of polymer used had a number average molar mass
(Mn) of 30 kg/mol, and a dispersity (Đ) of 1.9. Molar mass characteristics were
determined by size exclusion chromatography (SEC) at a flow rate of 1 mL/min in DMF
with 10 mM LiBr and 1% (v/v) NEt3 at 85 °C using a Waters 515 HPLC pump and
Waters Temperature Control Module II equipped with a Wyatt Optilab T-rEX
refractometer and two Plgel 5 μm mixed-D (300 mm × 7.5 mm) columns from Polymer
Laboratories by Varian connected in series. The calibration was performed using
poly(methyl methacrylate standards) (PMMA) standards. Poly(vinyl alcohol) (PVA) 488, 87-89% hydrolyzed and the 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) reagent were purchased from Millipore-Sigma
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(Oakville, ON). Concentrated (10x) phosphate buffer solution (PBS) was purchased from
Sigma Aldrich, and was mixed with deionized (DI) water from a MilliQ system, to create
1x PBS, pH 7.4. GSK3787 was purchased from Ontario Chemicals (Guelph, ON). DLS
was performed with a Zetasizer Nano ZS instrument from Malvern Instruments at 24.5
C. The Z-average diameter and polydispersity index (PDI) for each type of particle were
measured on three different batches of prepared particles. Differential scanning
calorimetry (DSC) was performed on a Q2000 from TA instruments (New Castle, DE).
The heating/cooling rate was 10 C/min from 0 to +200 C, and the data were obtained
from the second heating cycle. Statistical analyses were performed by one way ANOVA
(Microsoft Excel, 2016) with alpha set at 0.05, followed by a Bonferroni post-hoc
analysis, when applicable.

3.2.2

GSK3787 loaded particle preparation (PBSe-GSK3787)

Particles loaded with the PPAR antagonist, denoted as PBSe-GSK3787, were prepared
through an oil-in-water emulsification evaporation method. The dispersed phase of the
emulsion was made by dissolving 400 mg of PBSe in 200 mL of a 50:50 mixture of
CHCl3 and CH2Cl2. 37.5 mg of GSK3787 was added to the dispersed phase
simultaneously and was dissolved completely by stirring. The continuous phase was
prepared by dissolving 5.0 g of PVA in 1.0 L of DI water, in a 5 L beaker. The emulsion
was formed by slowly pouring the dispersed phase into the continuous phase, while
mixing vigorously using a Waring Commercial immersion blender, set to low (~9000
rpm). The solution was continuously mixed at 9000 rpm for an additional 2 min. The
resultant emulsion was immediately transferred to a 1 L beaker ensuring that the liquid
filled the beaker entirely, before being covered with aluminum foil, perforated with five
holes to slow the evaporation rate. The organic solvent was evaporated under constant
stirring in a fume hood for 24 h. The emulsion was then transferred to 50 mL centrifuge
tubes, which were spun at 2800 g for 10 min. Solid particles sedimented at the bottom of
centrifuge tubes, and the aqueous layer was discarded. Particles in the tubes were
resuspended in 50 mL of DI water, and were spun again for 10 min at 2800 g to wash the
particles. After removing the aqueous layer, the particles were collected by resuspending
the contents of each centrifuge tube in 5 mL of DI H2O. Fractions from different
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centrifuge tubes were combined, and frozen overnight at -20 C, before being
lyophilized. The dried samples were kept refrigerated at 4 C until use.

3.2.3

Non-drug-loaded particle preparation (PBSe-NDL)

Particles without drug were prepared by the same method as for PBSe-GSK3787 except
that no drug was added to the dispersed phase.

3.2.4

Dye-labeled particle preparation

When required for microscopic and stereoscopic examination, particles with dyes loaded
into them were prepared by the same method as for PBSe-GSK3787, with the addition of
either 5 mg of Nile red or 5 mg of IR-780 into the dispersed phase of the emulsion
instead of GSK3787.

3.2.5

Scanning electron microscopy (SEM)

SEM was performed in the University of Western Ontario’s Nanofabrication Facility
using a Zeiss LEO 1530 instrument, operating at 2.0 kV and a working distance of 6 mm.
Lyophilized samples of particles were mounted to stubs covered in carbon tape and
coated with a 10 nm layer of Osmium, using an SPI Supplies, OC-60A plasma coater.
Micrographs of the particles were taken, and images were produced to measure the size
of particles. Particles in three different images and three representative sections
(~30 × 30 μm) per image were measured to calculate the average diameters ± standard
deviation.

3.2.6

Determination of drug loading and encapsulation efficiency

10 mg of PBSe-GSK3787 particles were weighed gravimetrically using an analytical
balance. The particles were then completely dissolved in 1 mL of dimethyl sulfoxide
(DMSO). 20 μL of the DMSO was taken and added to 980 μL of the high performance
liquid chromatography (HPLC) mobile phase, a 40:60 mixture of acetonitrile and DI
water. Samples were filtered with 0.2 μM membrane filters prior to injection. HPLC
analysis was then performed using an instrument equipped with a Waters Separations
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Module 2695, a Kinetex C18 5 μm (4.6 × 100 mm) column connected to a C18 guard
column, and a Photodiode Array (PDA) Detector (Waters 2998). The PDA detector was
used to monitor GSK3787 absorbance at 238 nm. An isocratic eluent method with
acetonitrile and DI water (40:60) was used. The retention time of GSK3787 was 2.5
minutes. The calibration curve was obtained by spiking the mobile phase with known
concentrations of GSK3787, to form the following standard solutions: 100, 50, 25, 10, 5,
and 1 μg/mL GSK3787. All samples were filtered through 0.2 μm membrane filters, and
100 μL was injected using the instrument method described above. Three different
particle preparations were used to evaluate drug loading and encapsulation efficiency,
and each injection was performed in duplicate. Drug loading and encapsulation efficiency
were calculated according to equations (1) and (2).
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
) 𝑥 100 (1)
% 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 = (
𝑇𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
% 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦
𝐴𝑐𝑡𝑢𝑎𝑙 𝐺𝑆𝐾3787: 𝑃𝐸𝐴 𝑚𝑎𝑠𝑠 𝑟𝑎𝑡𝑖𝑜
) 𝑥 100 (2)
=(
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚𝑎𝑥. 𝐺𝑆𝐾3787: 𝑃𝐸𝐴 𝑚𝑎𝑠𝑠 𝑟𝑎𝑡𝑖𝑜

3.2.7

Atomic force microscopy of PBSe-GSK3787 and PBSe-NDL

Particles were resuspended in PBS, and deposited on glass coverslips, dropwise. After
allowing liquid to evaporate at ambient temperature overnight, the samples were used for
AFM imaging and mechanical testing. AFM measurements were carried out using a
BioScope Catalyst AFM (Bruker) mounted on an inverted microscope (LSM 510, Zeiss).
For indentation measurements, samples were immersed in water and heated to 37 C,
using the BioScope II Heater Stage and Veeco/LakeShore 331S Temperature Controller.
Pyramidal silicon nitride MSCT cantilevers (Bruker) with a nominal spring constant of
0.1 N/m were used for contact mode imaging and indentation measurements.
Determination of the spring constant of all cantilevers was carried out using the thermal
noise method.45 Images were recorded in air at a line rate of 1 Hz. For indentation
measurements, the ‘point and shoot’ mode of the BioScope software was used. After
hydration of the sample, an AFM image of a nanoparticle was acquired. A grid of 10 × 10
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points was placed on the nanoparticle surface, and a force indentation curve was recorded
at each point at a force trigger of 5 nN. At each indentation position, the Young’s
modulus was determined by fitting a Hertz model (cone indenter) to the approach curve
using AtomicJ.46 100 different points on each of eight individual PBSe-GSK3787
particles and seven PBSe-NDL were used for measurements. Outliers from the data set
were removed using a 1.5 x IQR statistical method. Moduli were recorded as the mean 
standard deviation.

3.2.8

In vitro release of GSK3787

50 mg of PBSe-GSK3787 particles were resuspended in 1 mL of pH 7.4 PBS containing
2 wt% of polysorbate 80 (sink solution) to facilitate the dissolution of the released drug.
The particle suspension was then added into a float-a-lyzer dialysis cassette with a
molecular weight cut-off of 10 kDa. Free (non-encapsulated) GSK3787 (50 mg/cassette)
was also studied to ensure that the release of drug from the particles was not rate-limited
by drug dissolution. Samples were placed in sealed containers with 3 mL of sink solution.
All 3 mL of the sink solution was removed every 5 days for 30 days total and replaced
with fresh solution. The concentration of drug in the sink solution was analyzed as using
the HPLC method described above for the determination of the drug
loading/encapsulation efficiency. Three replicates were studied for each of PBSeGSK3787 and free drug and every HPLC injection was performed in duplicate. Release
was calculated as the cumulative percentage of drug in the sink solution as compared to
the total drug in the sample, and is reported as the mean  standard deviation.

3.2.9

Primary chondrocyte harvest and culture

IMAC cells were harvested from 5 day old CD-1 mouse pups, as previously described.47
Pups were sacrificed and fixated to dissection plates. Cartilage was removed from the
femoral heads, femoral condyles, and tibial plateaus. The tissue was then subjected to 1 h
(3 mg/mL) followed by 24 h (0.5 mg/ml) incubations in Collagenase D diluted in
Dulbecco’s Modified Eagles Medium supplemented with 2 mM L-glutamine, 50 U/mL
penicillin, and 0.05 mg/mL streptomycin at 37 °C under 5% CO2. The tissue fragments
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were then agitated, by pipetting, and were passed through a 50 M cell strainer. Cells
were isolated by centrifugation for 10 min at 1300 g, allowing the formation of a pellet.
The pellet was washed in PBS buffer 2 times, before being resuspended in fresh media.
Cells were counted by combining 40 L of the cell suspension in media with 40 L of
trypan blue, and pipetting up and down to mix. 10 L of the trypan blue/cell suspension
was added to a cell counter plate, and was run on a Bio-Rad TC20 Automated cell
counter. Cells were seeded in 96 well treatment plates at a density of 5000 cells/well, in
12 well plates at a density of 3.0 x 105 cells/well, or in 24 well plates at a density of 2.5 x
105 cells/well and were allowed to grow to confluency for 7 days, with the media being
replaced every 48 h. Animal work was performed in compliance with the guidelines of
The Canadian Council on Animal Care guidelines (University of Western Ontario
Protocol 2019-035).

3.2.10

Cytotoxicity of GSK3787 to IMAC cells

GSK3787 was dissolved in DMSO at a concentration of 10 mg/mL, and was added to cell
culture media to afford concentrations of 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 M.
To each cell-containing well of a 96 well plate, 110 L of treatment media was added,
and allowed to incubate with the cells for 48 h. Cells receiving media without drug served
as negative controls, and cells receiving sodium dodecyl sulfate at a concentration of 1
mg/mL served as positive controls for cell death. The media was then aspirated and
replaced with 110 L of media containing 0.5 mg/mL of MTT reagent, then the cells
were incubated for 4 h. The MTT containing media was aspirated and 50 L of DMSO
was added to each well to solubilize the resulting purple crystals. The plate was then
placed in a plate reader (Tecan Infinite M1000 Pro) and the absorbance at 540 nm was
measured to quantify the relative metabolic activities of the cells. Four biological
replicates were performed, as well as six technical replicates per plate.
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3.2.11

Cytotoxicity of PBSe-GSK3787 and PBSe-NDL to IMAC
cells

PBSe-GSK3787 particles were resuspended in cell culture media to afford concentrations
of 5, 10, 25, 50, 100, 150, 250, 500, 750 and 1000 g/mL. PBSe-NDL particles were
resuspended in media at the same concentrations. The suspensions were disinfected by
placing them under the UV light of the cell culture hood for 1 h. The MTT assay was
then performed as described above for GSK3787.

3.2.12

Brightfield imaging of IMAC cells treated with PBSeGSK3787 particles

PBSe-GSK3787 particles were resuspended in cell media at concentrations of 0, 25, 50,
100, 150, 250, 500, 750, and 1000 g/mL, and then sterilized under the UV light of the
cell culture hood for 1 h. Then, 2 mL of suspension was added to the cell-containing
wells of a 12 well plate and incubated for 48 h. Cells were imaged after 48 h of
incubation with particles under bright field mode using a Biotek Cytation 5 microscope at
20x magnification.

3.2.13

IMAC staining and confocal microscopy

PBSe-GSK3787-NR were resuspended in culture media at a concentration of 100
g/mL, then sterilized under the UV light of the cell culture hood for 1 h. 1 mL of the
particle containing media was added to each cell containing well, and then the cells were
incubated for 48 h. The media was then aspirated, and the cells were washed 3 times with
PBS before being fixed with a 4 wt% paraformaldehyde (PFA) solution for 10 min at
room temperature. After washing with PBS, 1 wt% Triton X-100 was added and cells
were incubated for 10 min at room temperature. Cells were washed with PBS again
before adding a 1% bovine serum albumin (BSA) solution and incubating at room
temperature for 30 min. AlexaFluor 488 Phalloidin stain (Sigma Aldrich, Oakville, ON)
was added to PBS at a concentration of 10 g/mL, then 1 mL of the PBS containing
AlexaFluor 488 was added to cells and incubated for 10 min at room temperature.
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Coverslips were washed with PBS before being removed, and fixed to glass slides using
Immunomount with DAPI (Fisher Scientific, Oakville, ON). Slides were stored in the
dark until imaging. Confocal microscopy was performed using a Zeiss LSM 900 confocal
microscope. A 3D rendering of confocal images was created using Oxford Intstruments
Imaris x64 software.

3.2.14

Ex vivo intra-articular injection of PBSe-GSK3787-IR

50 mg/mL suspensions of PBSe-GSK3787-IR were prepared, and 5 L was drawn up
into 0.5 mL veterinary insulin syringes. Four healthy, male C57BL/6 mice of various
ages were sacked under CO2. 5 L intra-articular injections of PBSe-GSK3787-IR were
performed on the medial side of left hind limbs. After injection, the limbs were resected
and cultured in tissue culture medium containing 500 mL of -minimum essential media
(MEM ), supplemented with 25 mg of ascorbic acid, 0.108 g/mL β-glycerophosphate, 1.0
mL BSA, 1.25 mL L-glutamine, and 10,000 g/mL pen-strep. Imaging was performed
using a Leica M165C stereo microscope. Images were taken after 7d of limb culture to
qualitatively assess the presence of particles in the joint, and any diffusion of the particles
through surrounding tissue.

Results and Discussion
3.3.1

Preparation and characterization of PBSe particles.

The PEA used in this study, PBSe (Figure 3.1), was selected as we have previously
demonstrated it to exhibit an acceptable host response in the joints of sheep.28 It was
prepared as previously reported, through the interfacial polycondensation of sebacoyl
chloride and the di-p-toluenesulfonic acid salt of the diamine-diester prepared from Lphenylalanine and 1,4-butanediol.37 The resulting PBSe was characterized by 1H NMR
spectroscopy (Appendix B, Figure B.1) and SEC (Appendix B, Figure B.2). The batch
of PBSe used in the current work had an Mn of 30 kg/mol and Đ of 2.0.
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Figure 3.1: Chemical structures of PBSe and GSK3787.
Both GSK3787-loaded particles (PBSe-GSK3787) and non-drug-loaded (PBSeNDL) control particles were prepared by an emulsification evaporation technique.48
Initially, we investigated application of our previously developed conditions for the
preparation of celecoxib-loaded PBSe particles, which involved 2 mg/mL of PBSe in
CH2Cl2, 30 wt% of celecoxib relative to PBSe, 5 mg/mL of PVA in DI water, and a 5:1
ratio of the continuous to dispersed phase. At similar drug loadings of GSK3787, and
even 10 – 15 wt% of GSK3787, particles formed, but were contaminated with nonparticle debris (Appendix B, Figure B.3). It was suspected that the drug was disrupting
the interface and/or might not exhibit high compatibility with the PEA. Upon lowering
the amount of GSK3787 to 8.6 wt% relative to PEA, spherical particles were formed
cleanly (Figure 3.2A). In addition, it was found that the formation of particles was tied to
the evaporation rate of the organic phase of the emulsion, with a slower evaporation rate
allowing for more consistent particle formation, with less debris. The evaporation rates of
emulsions and their effect on resultant particles has been previously studied, and the
results of these studies agree with the assertion that the slower rate of evaporation used
herein, is more effective for particle preparation.49, 50 To slow the evaporation rate, the
dispersed phase was also changed from CH2Cl2 to 1:1 CHCl3:CH2Cl2. The evaporation
rates of these two organic solvents has been studied in the past, with CHCl3 having a
slower evaporation rate.51 Furthermore, the dissolution of PEA and drug were faster and
more complete in the solvent mixture than in pure CH2Cl2. Overall, these results
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indicated that particle preparation methods cannot necessarily be applied to different
drugs but that adjusting of the preparation parameters can overcome this challenge.
PBSe-NDL particles were prepared under the same conditions as PBSe-GSK3787
particles.

Figure 3.2: Scanning electron micrographs of particles (A) PBSe-GSK3787 and (B)
PBSe-NDL particles showing their spherical morphologies and diameters in the solid
state; (C) DLS diameter distributions by volume % of PBSe-GSK3787 and PBSe-NDL
particles showing the smaller diameters of the drug-loaded particles.
Particles were first assessed for their morphology by SEM. The particles prepared
using 8.6 wt% GSK3787 or with no drug had consistent spherical shapes, and no major
surface defects were observed (Figure 3.2 A,B). PBSe-NDL particles had some debris as
previously reported.28 In previous work the debris was believed to PVA, as evidenced by
the presence of a secondary Tg present in the DSC traces. Based on SEM analysis, PBSeGSK3787 particles had a diameter of 580  290 nM, while PBSe-NDL particles had a
diameter of 870  74 nm (Table 3.1). The Z-average particle diameters measured by DLS
were 530  54 nm for PBSe-GSK3787 and 790  64 nm for PBSe-NDL. Thus, the
diameters obtained for the two techniques were quite similar. PBSe-GSK3787 particles
were smaller than PBSe-NDL particles, but the dispersity of PBSe-GSK3787 measured
by SEM was much higher, and thus the difference in diameters between drug-loaded and
non-drug-loaded particles was only statistically significant in the case of DLS. The
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reduction in particle diameter might arise from the drug having a role at the solvent
interface, as noted above.
Table 3.1: Physiochemical characteristics of PBSe-GSK3787 and PBSe-NDL
particles.

Based on HPLC analysis (Appendix B, Figure B.4) of dissolved particles, the drug
loading of PBSe-GSK3787 particles was 8.1  0.4 wt% and the encapsulation efficiency
was 94  5%. The high encapsulation efficiency can be attributed to the high
hydrophobicity of GSK3787, which highly favours its partition into the dispersed phase,
and thus encapsulation into the particles. As noted above, the drug loading of GSK3787
was lower than what was previously obtained with celecoxib, due to differences in the
particle preparation procedure. However, this lower loading should not be a major issue.
GSK3787 is known to bind to PPAR through covalent modification of cysteine 249 on
the protein, which should lead to high potency.18
DSC was performed to assess the integration of drug within the particles. Both
PBSe-GSK3787 and PBSe-NDL showed similar glass transition temperatures of 35 C
and 34 C, respectively. In addition, a sharp Tm was noted for the drug at 190 C, and a
broad Tm was observed for PBSe-GSK3787 at about 187 C. The presence of a melting
transition in the particles suggests that crystalline domains of GSK3787 were present
within the particles and that the drug and polymer were likely phase separated. The broad
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transition can be attributed to domains of varying sizes. Previously, we observed
homogeneous incorporation of celecoxib into PBSe particles, as evidenced by an
increased Tg for the celecoxib-loaded particles, and no discernable Tm, despite the drug
having a melting point at 158 C.28 These results may explain why it was possible to
incorporate celecoxib at a much higher loading of >20 wt% compared wot 8 wt% for
GSK3787. Unlike in previous work, no secondary Tg was seen corresponding to excess
PVA, which was hypothesized to be attributed to the increased evaporation time,
resulting in more stable emulsions and PVA that was more effectively incorporated into
particles.

Figure 3.3: Differential scanning calorimetry of GSK3787, PBSe-NDL, and PBSeGSK3787. DSC shows a Tm for the drug and for phase separated drug in the particles.
Particles both with and without drug had very similar Tg values, again suggesting phase
separation of the drug in the particles.
In previous work, we characterized the Young’s modulus of bulk PEA and its blends with
celecoxib by tensile testing in water at 37 C.28 However, the mechanical properties of
the individual particles are important for their application in the joint, so in the current
work AFM was used to measure the Young’s moduli of individual particles by
compression with the AFM tip at 37 C in water and fitting of the data to the Hertz model
(Figure 3.4).52 PBSe-GSK3787 particles had a Young’s modulus of 2.8  1.0 MPa,
significantly lower than the PBSe-NDL particles, which had a Young’s modulus
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measured at 8.0  1.4 MPa. A reduction in modulus was also observed previously when
celecoxib was incorporated into bulk PBSe, and was attributed to increased plasticization
of the polymer by water due to the capability of the drug to hydrogen bond to water.28
This explanation may also apply to GSK3787 as it is also capable of hydrogen bonding.
The compressive modulus of joint articular cartilage has been reported to range from 0.08
to 2 MPa, depending on the depth of tissue.53, 54 Therefore, the PBSe-GSK3787 particles
have moduli that are similar to cartilage, which should minimize the potential for
mechanical irritation to occur. If necessary, the modulus could be further reduced by
varying the PEA structure.

Figure 3.4: AFM image of a PBSe-GSK3787 particle. (A) showing the grid
corresponding to the measurement of the modulus taken at 100 different points on a
particle. (B) Representative approach and withdrawn curves that were used to calculate
the modulus.

3.3.2

In vitro release of GSK3787

The release of GSK3787 was measured by placing a suspension of PBSe-GSK3787
particles inside a dialysis cassette and then quantifying the concentration of drug in the
dialysate over time by HPLC. The experiment was performed at 37 C in PBS containing
2 wt% of polysorbate 80, to enhance the solubility of the drug in the release medium. The
release medium was changed at each time point to ensure sink conditions. A suspension
of free powdered GSK3787 placed in a dialysis bag was used as a control to ensure that
the release was not rate-limited by simple dissolution of the drug. PBSe-GSK3787
exhibited a slow release of drug, with only 11% of GSK3787 released after 30 days with
no burst release observed. In contrast, 60% of the free GSK3787 was released into the
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dialysate over the at the same time period showing that the drug release for PBSeGSK3787 was not limited by the dissolution rate of the drug (Figure 3.5). Previous
results have suggested a surface erosion degradation mechanism for PBSe particles, and
this mechanism may help explain the slow and apparent zero-order release of drug.28
Representative HPLC traces are shown in Appendix B, figure B.4 and B.5, respectively.

Figure 3.5: Cumulative release of GSK3787 at 37 C in PBS containing 2 wt%
polysorbate 80. Slower release of GSK3787 was observed from PBSe-GSK3787
particles compared to the free drug. Error bars correspond to the standard deviations on
three separate particle populations in dialysis bags.

3.3.3

Cytotoxicity of GSK3787, PBSe-GSK3787, and PBSe-NDL
on primary cell cultures

IMAC cells were used in this study as they are primary cells harvested directly from
immature murine pups, allowing for a cell population that is as close to cartilage as
possible. Specifically, when isolated and cultured properly, IMAC cells express a number
of biomarkers that are found on chondrocytes in vivo, making them a good model for
chondrocytes.55 Free GSK3787 was first tested for cell toxicity by examining its effects
on the metabolic activity using the MTT assay. No significant toxic effects were observed
up to 100 M of drug, with metabolic activities remaining greater than 80% relative to
control cells not exposed to drug (Figure 3.6A).
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Figure 3.6: Metabolic activity of IMAC cells, as measured by MTT assay. 48 h after
treatment with A) increasing concentrations of the PPARδ inhibitor, GSK 3787 and B)
PBSe-GSK3787 and PBSe-NDL particles. No significant toxicity was observed for the
free drug or for PBSe-NDL. However, a trend towards higher toxicity was observed for
PBSe-GSK3787 particles. Error bars correspond to standard deviations (N = 4).
The effects of PBSe-GSK3787 and PBSe-NDL particles on IMAC cells were also
evaluated using the MTT assay. There was a trend towards higher toxicity for the PBSeGSK3787 particles, but the metabolic activities remained above 68% of the control even
at 1000 g/mL, the highest concentration tested (Figure 3.6B). It should be noted that at 8
wt% drug loading, 1000 g/mL corresponds to 80 g/mL (~200 M) of drug. However,
based on the drug release study, only a small fraction of drug should be released during
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the 48 h incubation, so toxic concentrations of released drug would not be expected in the
assay. Instead we proposed that any toxicity might arise from direct interactions between
the particles and the cells. Thus, we also imaged live IMAC cells using brightfield
microscopy after 48 h incubation of PBSe-GSK3787 particles with cells. The 150 g/mL
particle-treated cells were visible, and had healthy morphologies compared to control
cells that were not treated with particles (Figure 3.7). At 1000 g/mL, the cells were
remarkably covered with particles. It is possible that particle coverage on the cells limited
the transport of nutrients or MTT reagent to cells, reducing their apparent metabolic
activity.

Figure 3.7: Brightfield images of live IMAC cells. Treated with A) no particles; B) 150
g/mL of PBSe-GSK3787 particles; C) 1000 g/mL of PBSe-GSK3787 particles. The
particles agglomerated and adhered to the outsides of the cell membranes. Healthy cell
morphologies were observed for cells treated with 150 g/mL, whereas the cells were
almost completed coated with particles at 1000 g/mL.
Confocal microscopy of IMAC cells treated with PBSe-GSK3787-NR. Nile redlabeled PBSe-GSK3787 particles (PBSe-GSK3787-NR) were prepared to enable
visualization of the particles using fluorescence confocal microscopy. IMAC cells were
incubated with 100 g/mL of PBSe-GSK3787-NR particles for 48 h, and then imaging
was performed to assess the how particles interacted with the cells and whether they were
taken up by the cells. The cell cytoskeletons were also stained with AlexaFluor 488Phalloidin (green) and the nuclei were stained with DAPI (Figure 3.8A). A 3D image
rendering of the confocal images showed that the particles remained at the cell surface
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(Figure 3.8B). The particles were somewhat agglomerated, and thus concentrated in
certain regions rather than being uniformly distributed on the cell surfaces. It is likely that
some particles that were initially on cells were washed away through the numerous
washing steps that were associated with the staining of the cells.

Figure 3.8: Confocal microscopy images of IMAC cells. Treated with 100 g/mL
PBSe-GSK3787-NR particles (red) for 48 h, then stained with AlexaFluor 488 Phalloidin
(green, cytoskeletons) and DAPI (blue, nuclei): A) 2D image showing agglomerates of
particles on the cells; B) 3D rendering of cells showing particles localized at the cell
surface and not taken up by the cells.

3.3.4

Ex vivo intra-articular injections

For intra-articular injections, the particles were labeled with the hydrophobic green dye
IR780 (PBSe-GSK3787-IR) to provide contrast against tissues in brightfield imaging as
well as fluorescence at 485 nm for fluorescence microscopy. Murine knee joints were
obtained from C57BL/6 mice, and were injected with 5 L of a 100 mg/mL suspension
of particles per joint into the intra-articular space. The joints were then resected and
cultured in organ culture media for 7 d. The culture of joints has been determined
previously to be a good model for the study of OA, because of its low expense, and
ability of the tissue to maintain cytokine stimulation and osmotic pressure while in
culture.56 The joints were imaged to qualitatively assess the diffusion of particles away
from the joint space and through the surrounding tissue. Using brightfield imaging, it was
observed that distribution of particles had remained localized to the joint after 7 d, with
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no distinct green dye seen outside of the joint space. Fluorescence microscopy at 7 d
showed that while there was particle migration through both the joint and the limb, the
bulk of the injected material remained within the joint space (Figure 3.9). Thus, the
injection into joints ex vivo allowed for a better understanding of the distribution of
particles post administration, and how they behave in the absence of mechanical loading.

Figure 3.9: Representative knee joint explant from a C57BL/6 mouse that was
injected with 5 L of a 100 mg/mL suspension of PBSe-GSK3787-IR particles. Upon
resection of the limbs, images were taken with a stereoscope to determine injectability
and localization of particles. Images taken 7 days post injection of (A) Knee joint at 7.3x
magnification; (B) Knee joint at 1.6x magnification; (C) Particles as visualized in the
joint under fluorescence microscopy, 1.6x magnification.

Conclusions
PBSe particles containing the PPAR antagonist, GSK3878, were successfully prepared
by modifying our previously developed procedure. Specifically, it was important to lower
the loading of drug from 30 wt% for celecoxib to 8.6 wt% for GSK3787 in order to
achieve clean particle formation. This requirement may arise from GSK3787 acting at the
interface, as supported by the formation of smaller particles in the presence of this drug,
or due to incompatibility of the drug and PBSe, which was suggested by thermal analysis
of the particles. Relative to particles without drug, the loading of GSK3787 into the
particles lowered the Young’s modulus, bringing it closer to the natural range of articular
cartilage. The particles exhibited a slow release of GSK3787 in vitro with no burst
release observed. GSK3787 exhibited low toxicity to IMAC cells as indicated by the
MTT assay. The particles exhibited low toxicity, except at the highest concentrations
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studied (> 500 g/mL) and this lowering of metabolic activity might be due to the high
concentrations of particles localized on the cell surface, as indicated by bright field and
fluorescence confocal microscopy. Knee joint explant cultures that were injected with
particles showed that the particles remained localized in the joint, even after 7 days of
injection. Therefore, this system encapsulates and releases a potent PPAR antagonist
that cannot be delivered systemically, and serves as a promising vehicle for further
investigated in intra-articular drug delivery for the treatment of OA.
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Chapter 4

4

Thermo-responsive hybrid particle in hydrogel delivery
system for intra-articular drug delivery
Introduction

Osteoarthritis (OA) is a debilitating disease characterized by the degradation of articular
joints.1 The disease affects the entire joint, including the cartilage, synovium and
surrounding bones, and is estimated to be present in 242 million people worldwide.1-3
Incidence of the disease is rising rapidly; a 75% increase in years lived with disease was
reported between 1993 and 2013 worldwide.3 Current treatments focus on alleviating the
symptoms of the disease, as no disease modifying agents currently exist for OA.
Recently, significant research has focused on the discovery of potential diseasemodifying drugs, and a number of compounds are being studied, which act by a variety
of different mechanisms. Examples include CNTX-4975, which targets the capsaicin
receptor (TRPV1) and acts to relive pain associated with OA,4 while doxycyline hyclate,
a matrix metalloproteinase (MMP) inhibitor, acts to inhibit the enzymatic degradation of
cartilage.5 Our lab has identified PPAR receptors as potential targets,6, 7 where treatment
with antagonists such as GSK37878 could potentially lead to slowing or halting of OA
progression.6-8
Localized delivery of therapeutics via intra-articular (IA) injection is recognized as a
promising strategy to achieve the correct dose of drug in the joint, while reducing
systemic side effects.9 However, free drugs are subject to rapid clearance from the joint
by the lymphatic system over 1-4 h.10 Given that IA injections should not be given more
than once every few months,11 drugs delivered by IA may not reside in the joint for a
sufficient time period to provide a therapeutic effect. To address this, drug delivery
systems are needed, which are capable of prolonging the release of drugs in the joint
following injection.

119

To date, multiple types of injectable IA delivery systems have been studied for OA
treatment, including crystalline drug formations,12 liposomes,13-15 nanoparticles,16-19
microparticles,16, 20 and hydrogels.21, 22 Particle-based delivery systems for IA injection
have been extensively studied. For example, poly(lactic-co-glycolic acid) (PLGA)
particles loaded with triamcinolone acetonide were recently approved by the United
States Food and Drug Administration (FDA) for use as an OA treatment.23 Poly(ester
amide) (PEA) particles have also been investigated and were found exhibit good host
response in the joints of sheep and rats.19, 24 Despite progress with particles, sustained
drug release over multiple months remains a challenge. For example, the aforementioned
PLGA particles released triamcinolone acetonide at measurable levels for 6 weeks.23, 25
Despite their slow release in vitro, we also found in preliminary experiments with PEA
particles that drug release was not sustained within the joints of sheep, possibly due to
mechanical or biochemical degradation of the particles in the joint or due to their
trafficking to the synovial membrane.19 (Villamagna, I.J. unpublished results)
Hydrogels are another class of promising materials for IA delivery. They typically have
compression moduli less than that of cartilage, and have been shown to be well tolerated
in the joint.26 Furthermore, the macroscopic dimensions of hydrogels allow them to
remain in the synovial space for a prolonged period post-injection, potentially leading to
sustained release of drugs. Thermo-responsive hydrogels based on poly(caprolactone-colactide)(PCLA)-poly(ethylene glycol)(PEG)-PCLA have been investigated for IA
delivery of the non-steroidal anti-inflammatory drug celecoxib (CXB).22, 27-29 Drugloaded formulations of these polymers exist as injectable liquids at and below room
temperature, but gel spontaneously at 37 ºC following injection. When the polymers were
end-capped with acetyl groups, gelation was disrupted by drug loading and the resulting
hydrogels released therapeutic levels of (CXB) over 10-15 days, with an initial burst
release.21, 22 The addition of methacrylate end caps to the polymer allowed for covalent
crosslinking using a potassium persulfate (KPS)/tetramethylethylenediamine (TEMED)
initiation system, resulting in improved mechanical properties of the hydrogels, reduced
burst release, and sustained release of therapeutic celecoxib levels for more than 30 days
in an equine model.21 However, to reduce the required injection frequency, it is still
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necessary to eliminate the burst release and prolong the time of therapeutic drug levels in
the joint to ~3 months.
Here we explore a hybrid delivery system in which PEA particles are encapsulated into
covalently crosslinked PCLA-PEG-PCLA hydrogels (Figure 1). We propose that the
hydrogel should afford mechanical and biochemical protection of the particles in the joint
and retain the particles in the joint space, ultimately leading to more sustained release.
We focus on encapsulating the potential disease-modifying agent GSK3787.6, 7 The
particle-in-gel hybrid system was compared against drug-loaded and non-drug-loaded
gels to determine the effects of particle incorporation on hydrogel syneresis, degradation
rate, drug release, mechanical and rheological properties, as well as in vitro cytotoxicity.

Figure 4.1: Schematic illustrating the proposed particle in hydrogel hybrid drug
delivery system

Materials and Methods
4.1.1

General materials and procedures

The poly(ester amide) PBSe, composed of L-phenylalanine, 1,4-butanediol, and sebacic
acid, was prepared and characterized according to previously reported procedures.30
PBSe was used to prepare GSK3787-loaded particles (PBSe-GSK3787) as described in
section 3.2.2, and the particles were characterized by dynamic light scattering and
scanning electron microscopy as described in section 3.2.1. Methacrylate end-capped
PCLA-PEG-PCLA was synthesized and characterized as previously reported.21 KPS and
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TEMED were obtained from Sigma Aldrich (Oakville, Canada). GSK3787 was
purchased from Ontario Chemicals Inc. Acetonitrile was purchased from VWR
Analytical (USA). Phosphate buffered saline (PBS) powder packs were purchased from
Sigma Life Science and were used to prepare the pH 7.4 PBS solutions according to the
manufacturer’s instructions. Water used to prepare the buffer solutions was obtained from
a Barnstead Easypure II system with a measured resistivity of 15 MΩ or greater. All
other chemicals were used as received. Differential scanning calorimetry (DSC) was
performed on a Q2000 from TA instruments (New Castle, DE). The heating/cooling rate
was 10 C/min from -80 to +200 C, and the glass transition (Tg) and melting point
temperatures (Tm) were obtained from the second heating cycle.

4.1.2

Preparation of hydrogels

5.0 g (22 wt%) of molten polymer was added to 17.5 mL of PBS at 4 C and then
vortexed for 60 s. The mixture was then placed in a 37 C oven for 1 h, and then returned
to the fridge for 96 h to achieve complete dissolution. This base formulation was then
used to prepare different hydrogel systems. Control hydrogel consisted only of the base
formulation. 10 wt% particle-in-gel was prepared by adding 1.0 g of PBSe-GSK3787
particles to 9.0 mL of base formulation. 10 wt% GSK3787 was prepared by mixing 100
mg of GSK3787 with 900 L of formulation. Dispersion of the drug or particles in the
formulations was achieved by vortexing vigorously over 30 min. Covalent crosslinking
was initiated by adding 60 µL of KPS solution (0.18 M) and 20 µL of TEMED solution
(1 M) per mL of polymer formulation to produce a final concentration of 10 mM KPS
and 20 mM TEMED at 4 C, then the temperature was increased to 37 C.

4.1.3

Scanning electron microscopy (SEM)

To prepare samples, 1 mL of hydrogel formulation, prepared as described above, was
placed in a 3 mL vial and then gelled at 37 C for 1 h. Samples were removed from the
vials, affixed to stubs that had been covered in carbon tape, immediately submerged in
liquid N2 for 5 min, then lyophilized. They were then coated with 5 nm of osmium using
a SCI Supplies, OC-60A plasma coater. SEM was performed at the Western
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Nanofabrication Facility using a Leo 1530 instrument, operating at 2.0 kV and a working
distance of 6 mm.

4.1.4

Measurement of hydrogel syneresis

Water loss from prepared hydrogels was measured gravimetrically. 1.0 g of liquid
hydrogel was placed in a pre-weighed 3 mL screw top vial, and then placed in a 37 C
oven, and allowed to gel. At specified time points, vials were removed, uncapped, and
inverted for one min, allowing released water to flow from the vial. Vials were then
weighed before being recapped and placed back in the oven. Measurements were
performed on three different samples for each hydrogel system.

4.1.5

Hydrogel degradation

Gravimetric analysis was performed on hydrogel samples that had been soaked in pH 7.4
PBS at 37 C. 1.0 g of hydrogel was added to a 3 mL pre-weighed vial, and then the vial
was placed in a 37 C oven, and allowed to gel for 30 min. 2 mL of PBS was added to the
vial and it was returned to the 37 C oven. At specified time points, vials were inverted
for 1 min, allowing the PBS to drain completely, and were re-weighed. 2 mL of PBS was
then added to the vial again and it was placed back in the 37 C oven until the next time
point. The measurements were performed on three separate hydrogel samples of each
hydrogel system.

4.1.6

Measurement of Young’s moduli under compression

Mechanical testing of hydrogel samples was performed using a CellScale Univert
(Waterloo, ON, Canada), using a 10 N load cell. The different formulations were gelled
in 3 mL syringes (internal diameter of 8.7 mm) at 37 C for 1 h, yielding cylindrical
samples of hydrogel in a 2:1 height:diameter ratio (1.0 mL of formulation). Samples were
immersed in PBS at 37 C and then loaded with uniaxial compression to a total strain of
30%, at a constant rate of 4%/s. Secant moduli, calculated as the slope between 5 and
20% strain, were determined. All systems were measured in triplicate.
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4.1.7

In vitro release of GSK3787 from hydrogels in PBS

The release of GSK3787 from 10 wt% GSK3787 and 10 wt% particle-in-gel was
measured in PBS at 37 C. Hydrogels were prepared in 3 mL syringes (1.0 mL each) as
described above for compression testing. The hydrogels were accurately weighed and
then placed into vials with 3.0 mL of the release medium, which was PBS containing 2
wt% Tween 80. Vials were placed in a 37 C incubator. At predetermined time points,
the release medium was removed and replaced with fresh medium. The removed medium
was filtered using a 0.2 μm PTFE membrane syringe filters and analyzed for drug using
high performance liquid chromatography (HPLC). The HPLC instrument consisted of a
Waters 2695 Separations Module, a Kinetex C18 5 μm (4.6 × 100 mm) column
connected to a C18 guard column, and a Photodiode Array (PDA) Detector (Waters
2998). The PDA detector was used to monitor GSK3787 at 238 nm. An isocratic eluent
method with acetonitrile and water (40:60) was used. The retention time of GSK3787
was 2.5 min (Figure S7). Standard solutions of 10, 5, 2, 1, 0.5, and 0.2 μg/mL were
prepared by adding GSK3787 to PBS buffer. 100 μL of sample was injected. Release
studies were performed in triplicate for each system and all samples were measured in
duplicate by HPLC.

4.1.8

Primary articular chondrocyte harvest and culture

Immature murine articular chondrocyte (IMAC) cells were harvested from C56BL/7
mouse pups as previously described.31 Cells were plated at a density of 3.0 x 105 cells in
96 well plates and then cultured in media composed of MEM, 10 mg/mL L-glutamine, 5
mg/mL pen/strep and high efficiency fetal bovine serum at a concentration of 5% (v/v)
for one week prior to the treatment of cells for in vitro testing. Animal work was
performed in compliance with the guidelines of The Canadian Council on Animal Care
guidelines (University of Western Ontario Protocol 2019-035).

4.1.9

Toxicity assays on IMAC cells

Treatment media was prepared by injecting 3 mL of liquid hydrogel formulation into 10
mL of pre-warmed cell culture media at 37 C. Centrifuge tubes were sealed and placed
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in an incubator for 14 days, with agitation of the tubes occurring every 48 h. After
soaking, the media was sterilized by filtration through a 0.2 m PVDF syringe filter, and
110 μL was added to each well for treatment. The three hydrogel preparations were
soaked in cell media for 14 days before being filtered. Cells were cultured with the media
for 48 h. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reagent
was dissolved in cell culture media at a concentration of 0.5 mg/mL and 110 L of the
MTT media was added to each well, before being incubated for 4 h at 37 C. The media
was then aspirated, and 50 L of DMSO was added to each well to solubilize the purple
crystals. The plate was then placed in a plate reader (Tecan Infinite M1000 Pro) and the
absorbance at 540 nm was measured to quantify the relative metabolic activities of the
cells. Four biological replicates were performed, as well as six technical replicates per
plate.

4.1.10

Statistical Analyses

When appropriate, one-way ANOVAs were performed using Microsoft Excel 2016, or
GraphPad Prism 8.0. ANOVA was followed by a Bonferonni’s post hoc test, when
applicable. P values were set to 0.05.

Results and Discussion
4.2.1

Preparation of materials

The PEA polymer PBSe (Figure 4.2A) was prepared as previously reported,37 and had a
number average molar mass (Mn) of 28 kg/mol and a dispersity (Đ) of 2.1 based on size
exclusion chromatography (SEC) (Appendix C, Figures C.1-C.2). PBSe-GSK3787
particles were prepared as described in chapter 3 of this thesis, with an alteration to the
shear mixing rate, which was increased to ‘high’ (18,000 rpm) setting with a Waring
Commercial Immersion Blender. They were measured to have a Z-average diameter of
390  31 nm, and a polydispersity index (PDI) of .375 based on dynamic light scattering
(Appendix C, Figure C.3) and SEM confirmed their spherical morphology (Figure 4.2B).
The loading of GSK3787 in PBSe-GSK3787 particles was 8.1  0.4 wt%.
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Figure 4.2: Chemical structures and particle SEM. A) Chemical structure of PBSe; B)
Representative SEM image of PBSe-GSK3787 particles; C) Chemical structure of
PCLA-PEG-PCLA.
Methacrylate end-capped PCLA-PEG-PCLA was synthesized by the tin(II) 2ethylhexanoate catalyzed ring-opening polymerization of L-lactide and ε-caprolactone
from 1500 g/mol PEG-diol, followed by reaction with methacrylic anhydride in the
presence of NEt3 as previously reported.21 The resulting polymer had an Mn of 3460
g/mol, PCLA/PEG mass ratio of 1.31, and a CL/LA ratio of 3.73 based on 1H nuclear
magnetic resonance (NMR) spectroscopic analysis (Appendix C, Figure C.4) and an Mn
of 5640 g/mol and a Đ of 2.13 based on SEC (Appendix C, Figure C.5).

4.2.2

Preparation and characterization of hydrogels

Drug-free control, GSK3787-loaded, and PBSe-GSK-3787 hydrogels were prepared
(Table 4.1). The hydrogel formulations were prepared by first dissolving PCLA-PEGPCLA at 4 C and then adding drug or particles. Gelation was induced by the addition of
KPS/TEMED, and increasing the temperature to 37 C. Gelation was qualitatively
complete after 30 min based on the vial flip test (Appendix C, Figure A18).
Table 4.1: Hydrogel preparations and their physiochemical properties.
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Hydrogel

Additive

Young’s
modulus
(kPa)

none

42.5  0.3

GSK3787

10 wt%

30.1 2.5

hydrogel

GSK3787

Control
hydrogel

PBSe-

10 wt% PBSe-

GSK3787

GSK3787

hydrogel

particles

16.3  3.1

The hydrogels were characterized by SEM after being flash frozen in liquid nitrogen, and
then lyophilized (Figure 4.3). Compared to the control hydrogel, the GSK3787
hydrogel had a different morphology, with plate-like structures throughout the material.
Spherical particles were clearly visible in the PBSe-GSK3787 hydrogel. DSC was also
performed to assess the incorporation of drug and particles into the hydrogel (Figure 4.4).
The control hydrogel had a Tg of -47 C, which is attributed to the PEG. Multiple
melting endotherms were present at 18 and 20 C, which is attributed to crystalline
caprolactone sequences. Direct incorporation of GSK3787 into the hydrogel caused a
disappearance of the melting endotherms, suggesting it disrupted the crystallization of the
caprolactone domains. A single Tg at -35 C was observed and no Tm for GSK3787 was
observed, which is present for the pure drug at 190 C, as shown in Chapter 3 (Figure
3.3). These results suggest a mixing of the drug and polymer domains, and are consistent
with previous results for the incorporation of CXB was into the same hydrogel system.21
In contrast, when PBSe-GSK3787 particles were incorporated into the hydrogel, the Tg
was -55 C, quite similar to that of the control hydrogel, and a single, broad melting
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endotherm was observed at 18 C. These results are consistent with the incorporation of
the particles into the aqueous domains of the hydrogel, as shown in Figure 4.1, where
they do not interfere with the assembly of the PCLA blocks.

Figure 4.3: SEM micrographs of: A) Control hydrogel; B) GSK3787 hydrogel; C)
PBSe-GSK3787 particles in hydrogel.

Figure 4.4: DSC thermograms for control hydrogel, GSK3787 hydrogel, and PBSeGSK3787 hydrogel. Direct incorporation of GSK3787 disrupts packing of the
caprolactone domains, resulting in disappearance of the melting endotherm, while the
incorporation of PBSe-GSK3787 particles does not greatly affect the thermal properties
relative to the control, likely due to their incorporation into the aqueous domains of the
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hydrogel. A small exotherm at –35 C in the PBSe-GSK3787 hydrogel likely
corresponds to cold crystallization.
The effects of drug and particle incorporation on the syneresis of the hydrogels were
investigated. We previously reported up to ~40 wt% water loss from non-covalent acetyl
end-capped PCLA-PEG-PCLA hydrogels depending on the incorporated drug, due to
collapse of the hydrogel network structure,32 whereas less than 10 wt% water loss was
observed for methacrylate capped PCLA-PEG-PCLA hydrogels that were covalently
crosslinked using KPS/TEMED.29 As shown in Figure 4.5, the water loss from the
control hydrogel, GSK3787 hydrogel, and the PBSe-GSK3787 hydrogel were also all
less than 10 wt%, showing that the incorporation of the particles or drug directly did not
result in network collapse to a large extent. However, after 12 h, the extent of syneresis
for the GSK3787 hydrogel was significantly higher than the control hydrogel
suggesting that direct incorporation of drug has the largest effect on the network collapse.

Figure 4.5: Syneresis of hydrogel systems. Measurement of the water loss from the
hydrogels showing less than 10% syneresis for the control, drug-loaded, and particleloaded hydrogels over 24 h. The Measurements were performed in triplicate and the error
bars correspond to the standard deviations.
Degradation of the hydrogels was also probed based on their mass loss into PBS at 37 C
(Figure 4.6). The control hydrogel degraded very slowly, with only 12% mass loss over
60 days. The incorporation of drug or particles resulted in more rapid degradation. The
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more rapid degradation of the GSK3787 hydrogel may result from disruption of the
crystalline packing of the caprolactone domains, which was evidenced by the thermal
analysis. Crystallinity is known to result in slower degradation of polycaprolactone.33
Incorporation of the particles in PBSe-GSK3787 hydrogel resulted in even faster
degradation. It is likely that the incorporation of particles into the gel hindered covalent
crosslinking to some extent, making the resulting gel more susceptible to degradation.
There was a statistically significant difference between the mass remaining for the PBSeGSK3787 hydrogel compared to control hydrogel at 60 d.

Figure 4.6: Percent mass remaining over time for hydrogel systems at 37 C, in PBS.
Incorporation of GSK3787 or PBSe-GSK3787 particles resulted in more rapid
degradation of the gels. All measurements were performed in triplicates, and the error
bars correspond to the standard deviations. Error bars on the control hydrogel are too
small to be visible.
The Young’s moduli of the hydrogels were measured under unconfined compression in
PBS at 37 C to mimic physiological conditions (Figure 4.7). The control gel had the
highest modulus of 42.5  0.3 KPa. This value is about 2-fold higher than that previously
reported for a similar hydrogel and can likely be attributed to small differences in the
polymer composition between the two studies. Incorporation of GSK3787 resulted in a
reduction in the modulus to 30.1 2.5 KPa while the incorporation of PBSe-GSK3787
particles further lowered the modulus to 16.3  3.1 KPa. These results correlate with the
observed degradation results, suggesting that the disruption of hydrophobic block
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packing or disruption of network formation reduce the hydrogel stiffness. Particle in
hydrogel systems have been previously reported, but their moduli under compression
have not been reported.34,35 Interestingly, Hu et. al, tested the tensile properties of a
particle in hydrogel system, and found that there was no statistical difference between the
moduli of hydrogels with and without particles, an opposite finding to the currently
described work.36

Figure 4.7: Stress-strain curves of three hydrogel systems, as measured in PBS at 37
C. All measurements were performed in triplicates, and the error bars correspond to the
standard deviations.
The release of GSK3787 from the GSK3787 hydrogel and PBSe-GSK3787 hydrogel
immersed in PBS at 37 C was measured over a period of 60 days. Polysorbate 80 was
added to the release medium at 2% wt/vol to facilitate the dissolution of the drug.19, 21, 3739

Slow release, without any initial burst was observed for both systems. When GSK3787

was loaded into the hydrogel, 44% was released over 60 days, which can likely be
attributed in part to hydrogel degradation and in part to slow dissolution and diffusion of
the drug from the hydrogel. Release from the PBSe-GSK3787 hydrogel was
significantly slower, with only 20% released over 60 days. In this case, the drug would
need to be first released from the particles, to be released from the hydrogel. Indeed, the
release of ~10% of GSK3787 over the first 30 days is in close agreement with the release
rate of GSK3787 from the particles themselves (Figure 3.5, Chapter 3). However, it is
well established that the release rates of drugs in vitro and in vivo may be very
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different.21, 22 For example, other factors such as mechanical forces, enzymes, proteins or
varying pH levels, could all affect the degradation of the hydrogels and/or the release
rates of drugs.40, 41 Under these conditions, the particle-loaded hydrogel and particles
alone may behave quite differently.

Figure 4.8: Release of GSK3787 from GSK3787 hydrogel and PBSe-GSK3787
hydrogel in PBS at 37 C. Slower release from the particle in hydrogel system is noted.
The experiments were performed in triplicate and the error bars correspond to the
standard deviations.

4.2.3

Primary cell toxicity from hydrogel systems

IMAC cells were harvested and used for the cell toxicity studies in this work because
their phenotype is very close to that of articular chondrocytes.42 By plating the cells and
not passaging them, the IMAC cells are less likely to de-differentiate into fibroblasts, an
issue that is very common with other cell lines such as ATDC5, that are used to study
cartilage.43 The cytotoxicity study was performed as a leachate study, in which the
hydrogels were soaked in media for 14 days at 37 C to allow any potentially toxic
species to leach from the hydrogels and then this media was added to the cells. After 48
h, an MTT assay was performed to assess cell metabolic activity. None of the three
hydrogel compositions, the control hydrogel, GSK3787 hydrogel and PBSe-GSK3787
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hydrogel showed significant toxicity from their degradation byproducts as the observed
metabolic activities were not statistically different than the control (Figure 4.9).
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Figure 4.9: Metabolic activity of IMAC cell cultures when treated with leachate
media from three different hydrogel preparations. Control hydrogel, GSK3787
hydrogel and PBSe-GSK3787 were soaked in media for 14 days before being added to
cells for 48 hours. Metabolic activity was tested by MTT assay. All samples were
performed with three biological replicates, and six technical replicates per plate. Plotted
as mean absorbance  standard error (N = 4).

Conclusions
This work resulted in the development a promising intra-articular drug delivery system
that combined two previously described drug delivery technologies: a thermos-responsive
hydrogel and poly(ester amide) particles. Hydrogels that were loaded with particles could
be prepared in the same manner as control and drug-loaded hydrogels, and showed
similar physiochemical characteristics. Inclusion of GSK3787 directly into the hydrogel
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resulted in increased syneresis, more rapid degradation, and a lower Young’s modulus
relative to the control hydrogel, likely due to its incorporation into the hydrophobic
PCLA domains and disruption of crystallinity. Incorporation of PBSe-GSK3787 particles
into the hydrogel did not significantly affect syneresis, but did result in more rapid
degradation and a lower Young’s modulus relative to the control hydrogel, likely due to
some interference with covalent crosslinking. However, these effects were relatively
modest, and these hydrogels are still more stable and much stiffer than physically
crosslinked thermo-responsive hydrogels that have been explored in vivo.21, 22 Drug was
released more slowly from the PBSe-GSK3787 hydrogel than from the GSK3787
hydrogel due to the requirement for the drug to be first released from the particles, then
from the hydrogel. Although the release rate for the PBSe-GSK3787 hydrogel was
similar to that reported in Chapter 3 for PBSe-GSK3787 particles in vitro, differences are
expected in vivo due to the ability of the hydrogel to mechanically shield the particles and
to retain the particles in the joint. In vitro cell toxicity assays showed that the hydrogels
do not release harmful byproducts over 14 days, and that they appear to be well tolerated
biologically. In future work, it will be important to evaluate whether the particle in
hydrogel system serves to provide sustained drug release in the joints of large and small
animals. In addition, the efficacy of these GSK3787-loaded hydrogels in preventing or
slowing the progression of OA in a model of post-traumatic OA should be evaluated.
Overall, the development of more drug delivery systems for IA use can help to overcome
some of the persistent challenges that IA drug delivery systems face, and can lead to a
system that can have a beneficial effect on the treatment of OA.
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Chapter 5

5

Conclusions and Future Work
Conclusions

Osteoarthritis (OA) continues to be a disease that affects a large number of people
worldwide, causing pain and disability. The prevalence of the disease continues to rise
annually, due in part to increasing lifespan and obesity around the world. Despite its
prevalence, disease modifying agents are still unavailable to treat OA, and most
pharmacologic therapies rely on pain reduction through systemic administration.
Systemic administration of pharmacologic therapy is well documented to lead to side
effects that can be life-threatening. In addition to systemic pain medications, a number of
new molecules have been developed that could potentially serve as disease modifying
agents in OA. GSK3787 is a potent peroxisome proliferator activated receptor (PPAR)δ
inhibitor that has been implicated as a potential disease modifying agent for OA.
Inhibition of the PPARδ receptor in a mouse model has shown the attenuation of OA
after surgical induction of post-traumatic OA. However, GSK3787 cannot be delivered
systemically, due to concerns about potential adverse side effects.
Intra-articular (IA) drug delivery has become increasingly recognized as a potential
strategy for the administration of OA drugs.1 IA injections can potentially deliver a
higher dosage of drug directly at the target tissue, while reducing systemic exposure to
the drug and potential adverse side effects. However, the removal of free drugs from the
IA space through lymphatic drainage remains a challenge. Drug molecules are typically
cleared within a few hours, so they often cannot reach their targets at sufficient levels
over the required period of time to achieve a therapeutic effect.2 Furthermore, it is
essential to minimize the frequency of IA injections (ideally ≤ once every 3 months) in
order to minimize discomfort for patients as well as potential complications associated
with injection.3, 4, 5
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Drug delivery systems developed for IA use have been proposed for achieving a
prolonged release of drug in the joint. To date, while a number of systems have been
investigated, challenges remain.1 Naturally derived hydrogels, based on hyaluronic acid,6
elastin-like peptides,7 or synthetically derived hydrogels based on poly(caprolactone-colactide)(PCLA)-poly(ethylene glycol)(PEG)-PCLA8, 9 have not exhibited sufficient
retention of drugs in the joint, and in many cases led to a burst release of loaded drug.
Nanoparticles based on block copolymers have also been explored,10,11 but they have
short retention times in the joint. Microparticles have been most extensively investigated.
Flexion Therapeutics has recently gained FDA approval for the use of Zilretta for the
treatment of OA.12 Zilretta is composed of poly(lactic acid-co-glycolic acid) (PLGA)
microparticles loaded with triamcinolone. While data from clinical trials has proven the
safety of Zilretta, the efficacy is still debated, with studies showing that the release from
the particles was not much longer than the effect of injections of corticosteroids to the
joint alone. Furthermore, there remain concerns with microparticle formulations for IA
delivery systems because of the potential for the particle degradation products to induce
adverse inflammatory reactions in the joint,13, 14 or for the particles to cause joint
irritation if their mechanical properties are not compatible with surrounding joint
tissues.15 While significant progress has been made towards the development of IA drug
delivery systems, a highly effective drug combined with a delivery system capable of
drug release over 3 months does not currently exist.
In Chapter 2, celecoxib, a commonly used non-steroidal anti-inflammatory drug
(NSAID) for OA treatment, was encapsulated in poly(ester amide) (PEA) particles. Two
different PEAs that had very similar chemical structures were investigated and compared.
Phenylalanine butanediol sebacic acid (PBSe) and phenylalanine octanediol sebacic acid
(POSe) only differ by four carbons in the diol component of the polymer, but the effects
of this small structural difference on the particles were significant. POSe had a lower
glass transition temperature, which made the particles more susceptible to agglomeration
and degradation. High loadings of celecoxib, greater than 20 wt% were achieved from
particles composed of both PBSe and POSe. However, the release of celecoxib in vitro
was much faster from POSe particles than from PBSe particles. Overall, these results
highlight that small differences in polymer structure can have profound effects on the
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properties of a delivery system, so polymers require careful structural tuning and
characterization of physicochemical properties.
Based on the physicochemical and drug release properties, PBSe particles were selected
for further evaluation as a drug delivery system. Two different cell lines, ATDC5 cells, as
well as C2C12 cells were studied. Toxicity was induced with a dose dependent manner
from celecoxib, but no significant cytotoxicity was noted from the particles alone. An
ovine model was used for in vivo studies. The injection of celecoxib loaded particles
yielded minimal host response, to the extent that was expected from the injection process
itself, suggesting that the particles were well tolerated. Furthermore, it was found that
particles had migrated into the synovial membrane. Overall, it could be concluded from
this work that PBSe particles warranted further investigated as an IA drug delivery
system.
Chapter 3 further explored the PBSe particle drug delivery system for encapsulation of
the PPARδ inhibitor GSK3787. To our knowledge, this is the first instance in which a
PPARδ inhibitor has been incorporated into a drug delivery system. The particles were
characterized physiochemically. The GSK3787 loaded particles were ~200 nm smaller in
diameter, and the incorporated GSK3787 existed in crystalline domains in the particles,
as evidenced by the presence of a melting transition for the drug. In addition, it was only
possible to load GSK3787 at 8.1 wt%, as compared to the 23 wt% for celecoxib. 8.1 wt%
should be sufficient to deliver a therapeutic dose in vivo due to the drug’s expected high
potency due to the non-reversible binding method of the GSK3787. From these results it
can be concluded that the application of a particle delivery platform to a different drug is
not always straightforward and optimization is required on a case by case basis.
Mechanical properties of individual particles were measured using atomic force
microscopy (AFM), and it was determined that the particles had a Young’s modulus close
to that of native cartilage tissue within the joint. The particles exhibited a slow release of
the loaded drug, and did not cause significant toxicity to IMAC cells, further leading to
the conclusion that PEA particles warranted further investigation as an intra-articular
delivery system. One limitation of the work was the absence of ovine controls that did not
have particles injected into the joints. This was not possible due to the nature of the large
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animal model as other joints in the animals had been used for other experiments in the
Hurtig lab. However our collaborator is experienced in evaluating the joints of sheep, so
was still able to make qualitative assessments based on the known histological results for
a normal joint.
While in vitro release of both celecoxib and GSK3787 from the particles were slow,
unpublished results in sheep measuring celecoxib concentration suggested that drug
concentrations were undetectable by 1 week and that drug release would not be
sufficiently sustained in vivo. The difference between the in vitro and in vivo results was
thought to arise from either trafficking of the particles out of the joint cavity to the
synovial membrane, or from mechanical or biochemical degradation of the particles. It
was proposed that encapsulation of the drug-loaded particle in a hydrogel would afford
protection and facilitate particle retention in the joint cavity. Chapter 4 described the use
of a thermo-responsive, covalently crosslinked hydrogel to encapsulate GSK3787 or
GSK3787-loaded particles. Physicochemical characterization led to the conclusion that
the incorporation of drug or particles within the hydrogel led to only modest changes in
their degradation rate and Young’s modulus. The release of drug was studied in vitro and
when drug loaded particles were embedded within the hydrogel, the amount of drug that
was released over 60 days was cut by roughly half as compared to hydrogels loaded with
drug directly. Based on these results, these hydrogel systems warrant further investigation
for IA delivery.
Though the studies encompassed in this thesis were designed with care and intended to be
comprehensive, limitations of the aforementioned work remain. Foremost, animal
studies that were performed in chapter 2 of this thesis were done in the absence of
controls. The use of a large animal model can pre-empt the ability to utilize all joints, and
control over sacrifice of the animals, leaving the study without a usable joint for a
control. Furthermore, release studies that were performed in this work were done in the
absence of degrative enzymes and biological factors that could have a large effect on the
release rate of the system. In this thesis, release studies were designed to show the slowed
release from a free release system, to compare between different compositions of
particles or hydrogels, or to serve as a model for prolonged release. The studies were not
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designed to make claims about the in vivo applicability of the aforementioned release
systems.
Overall, the research described here laid the groundwork for future testing to be done to
determine whether PPAR antagonists can slow or halt the progression OA. If successful,
these therapeutics can potentially serve as the first disease-modifying treatment for OA.
In addition, the platform delivery systems developed in this thesis can be used for the IA
delivery of other existing drugs ranging from NSAIDs to new potential therapeutics that
are currently under development in our lab and in other labs.

Future Directions
The proposed future research stemming from this project will first and foremost
determine the potential for PPAR antagonists to slow or halt the progression of posttraumatic OA. Studies of GSK3787-loaded hydrogel and GSK3787-loaded particles in
hydrogel utilizing a rat model that has OA surgically induced are planned, to determine if
the system provide a disease modifying response. If successful, further studies will be
performed in large animals, such as sheep, where the biomechanics more closely mimic
those of humans. It is expected that due to the nature of the studies required with
examining the efficacy of GSK3787, it would be advantageous to use a small animal
model that would be available for a larger amount of studies, such as sectioning,
dissection and testing of tissues. Larger animal studies will be reserved for in vivo release
studies and biocompatibility, both of which can be much easier to test in larger animal
models due to the larger size.
From a materials standpoint, particles have already shown promise for use in IA drug
delivery, and the PEA particles described in this thesis are still of interest for future
studies. In particular, it would be worthwhile to continue to screen different PEAs for use
in particle delivery systems. PEAs are known for their tunability, and changing the
polymer structures would allow for new drug delivery systems with significantly
different properties to be developed. In 2018, Bajpayee and Grodzinsky suggested that
more research be done on the utilization of electrostatic interactions in order to penetrate
into the cartilage tissue before releasing drug.16 The ability to develop systems that are
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charged, and are able to interact with the anionic surface of the cartilage is feasible, and
can provide new areas of research. PEAs provide an excellent opportunity for this, as
they have the ability to incorporate charges pendant to the polymer backbone17 which
could help move the particles through the charged tissues of the joint, thereby further
targeting the release of drug to more specific tissues.
In addition, the hydrogel platform delivery system can be further optimized, both
chemically and physically. Chemical modification would allow for new formulations that
can lead to “smart”, stimuli-responsive drug delivery systems. Further modification of the
properties of these delivery systems is proposed to develop the selective release of drugs
in response to chemical triggers associated with OA, such as enzymes, changes in pH or
reactive oxygen species. The development of systems that exhibit altered properties in
response to the aforementioned triggers opens up the possibility of “patient specific” OA
treatment, in which different amounts of medication will be released at different rates,
depending on the severity of disease in individual patients.
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Appendices

Appendix A: Supplemental Information for Chapter 2

Figure A.1:1H NMR spectrum of PBSe (DMSO-d6, 400 MHz).
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Figure A.2: 1H NMR spectrum of POSe (DMSO-d6, 400 MHz).

Figure A.3: SEC trace (DMF eluent containing 10 mM LiBr, refractive index detection)
for PBSe (Mn = 30 kg/mol and Đ = 2.0).
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Figure A.4:

SEC trace (DMF eluent containing 10 mM LiBr, refractive index

detection) for POSe (Mn = 18 kg/mol and D = 1.9).

Figure A.5: DSC thermograms of the drug-loaded and non-drug-loaded bulk polymers that
were prepared by the same melt pressing procedure as the samples for tensile testing
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described in the manuscript. The multiple melting peaks for POSe-NDL have been
commonly observed for PEAs and were attributed to the formation of different crystalline
domains.1 The exothermic peak preceding the melting transitions corresponds to cold
crystallization.
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Figure A.6: 1H NMR spectra of a) PBSe, b) CXB and c) PVA (DMSO-d6, 400 MHz).
Peaks used in the calculation of CXB loading are indicated with arrows. The same peaks
were used for calculation of POSe drug loading and encapsulation efficiency.
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Figure A.7: Representative 1H NMR spectra of PBSe-CXB particles. Three peaks are
identified and integrated for their use in calculation of CXB loading percentage and
encapsulation efficiency.
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Appendix B: Supplemental Information for Chapter 3

Figure B.1: 1H NMR spectrum of PBSe (DMSO-d6, 400 MHz). As used in Chapter 3.
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Figure B.2: SEC trace (DMF eluent containing 10 mM LiBr, refractive index detection)
for PBSe (Mn = 30 kg/mol and Đ = 2.0). As used in chapter 3.

Figure B.3: Scanning electron micrographs of particle formations with varying amounts
of theoretical GSK3787 drug loading percentages. Particles with 15 wt% of GSK3787
added to the dispersed phase of the emulsion did form, but in small numbers and with
large amounts of excess, non particle, material (left). Particles with 10 wt% of GSK3787
did form, and were of spherical morphology and had a good size distribution, but had
visible polymer remaining in the samples (right). Scanning electron micrographs of
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PBSe-GSK3787 (A) and PBSe-NDL (B) particle preparations were taken using a Leo
1530 scanning electron microscope at a working distance of 6mm, at 2kV.

Figure B.4: Representative HPLC trace of GSK3787 as measured for drug loading and
encapsulation efficiency of particles.
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Figure B.5: Representative HPLC trace of GSK3787 release in PBS from PBSeGSK3787, as measured for drug release studies from particles.
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Appendix C: Supplemental Information for Chapter 4

Figure C.1: 1HNMR spectrum of PBSe (400 Hz, DMSO-d6). As used in chapter 4.

Figure C.2: SEC trace (DMF eluent containing 10 mM LiBr, refractive index detection)
for PBSe (Mn = 28 kg/mol and Đ = 2.1). As used in chapter 4.
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Figure C.3: Volume and intensity distributions of PBSe-GSK3787 particle diameters as
measured by DLS. Intensity is shown on the top, volume distribution bottom. As used in
chapter 4.
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Figure C.4: 1H NMR spectrum of MA-PCLA-PEG1500-PCLA-MA (400 Hz, CDCl3).
Assignment of peaks used in the calculation of the composition of the polymer are
denoted by “a” which denotes the CH2 adjacent to the lactide group, “b” denotes the CH2
adjacent to a caprolactone unit, and “e” denotes a methacrylate unit. The PEG peak (d)
was set to 132 corresponding to 1500 g/mol. The number of LA units was determined
from the integration of the peak at 5.1 ppm and the number of CL units was calculated as
the sum of the integrations of peaks at 4.03 and 3.98 ppm divided by 2 protons per repeat
unit. Methacrylation % was calculated by comparing the integration of peaks labeled “e”
to that of PEG “d”.
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Figure C.5. SEC trace of MA-PCLA-PEG1500-PCLA-MA (DMF eluent containing 10
mM LiBr, refractive index detection) for PBSe (Mn = 5.4 kg/mol and Đ = 2.2). As used in
chapter 4.

Figure C.6: Vial inversion tests of hydrogel systems. Vial A corresponds to control
hydrogel, vial B corresponds to 10 wt% particle-in-hydrogel and vial C corresponds to 10
wt% GSK3787 in hydrogel. Left: Three hydrogel systems after the addition of KPS and
TEMED, at 4 degrees. Center: Three hydrogel systems pre-gelation. Right: Three
hydrogel systems with the addition of KPS and TEMED for physical crosslinking, post
incubation for 30 minutes at 37 °C.
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Figure C.7: Representative HPLC trace showing GSK3787 at 2.25 minutes retention
time.
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Appendix D: Permissions

Figure D.1: Permission for figure 1.1
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Figure C.2: Permission for figure 1.3.
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Figure C.3: Permission for figure 1.10.
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Figure C.4:Permission for Figure 1.11
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Figure C.5: Permission to reprint “Poly(ester amide) particles for controlled delivery of
celecoxib”, as seen in chapter 2.
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